<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<!-- saved from url=(0060)https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable -->
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><link type="text/css" rel="stylesheet" id="dark-mode-custom-link"><link type="text/css" rel="stylesheet" id="dark-mode-general-link"><style lang="en" type="text/css" id="dark-mode-custom-style"></style><style lang="en" type="text/css" id="dark-mode-native-style"></style><style lang="en" type="text/css" id="dark-mode-native-sheet"></style><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="">
                 <script async="" src="./Noonan-Syndrome-GeneReviews_files/gtm.js.download" id="pingerInjectedGTM"></script><script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books"><meta name="ncbi_pdid" content="book-part"><meta name="ncbi_acc" content="NBK1124"><meta name="ncbi_domain" content="gene"><meta name="ncbi_report" content="printable"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/NBK1124/?report=printable"><meta name="ncbi_app" content="bookshelf">
        <!-- Logger end -->
        
        <title>Noonan Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="./Noonan-Syndrome-GeneReviews_files/jig.min.css"><script type="text/javascript" src="./Noonan-Syndrome-GeneReviews_files/jig.min.js.download"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE"><meta name="citation_inbook_title" content="GeneReviews® [Internet]"><meta name="citation_title" content="Noonan Syndrome"><meta name="citation_publisher" content="University of Washington, Seattle"><meta name="citation_date" content="2022/02/17"><meta name="citation_author" content="Amy E Roberts"><meta name="citation_pmid" content="20301303"><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1124/"><meta name="citation_keywords" content="Dual specificity mitogen-activated protein kinase kinase 1"><meta name="citation_keywords" content="GTPase KRas"><meta name="citation_keywords" content="GTPase NRas"><meta name="citation_keywords" content="GTP-binding protein Rit1"><meta name="citation_keywords" content="Leucine-zipper-like transcriptional regulator 1"><meta name="citation_keywords" content="RAF proto-oncogene serine/threonine-protein kinase"><meta name="citation_keywords" content="Ras GTPase-activating protein 2"><meta name="citation_keywords" content="Ras-related protein M-Ras"><meta name="citation_keywords" content="Ras-related protein R-Ras2"><meta name="citation_keywords" content="Serine/threonine-protein kinase B-raf"><meta name="citation_keywords" content="Son of sevenless homolog 1"><meta name="citation_keywords" content="Son of sevenless homolog 2"><meta name="citation_keywords" content="Tyrosine-protein phosphatase non-receptor type 11"><meta name="citation_keywords" content="BRAF"><meta name="citation_keywords" content="KRAS"><meta name="citation_keywords" content="LZTR1"><meta name="citation_keywords" content="MAP2K1"><meta name="citation_keywords" content="MRAS"><meta name="citation_keywords" content="NRAS"><meta name="citation_keywords" content="PTPN11"><meta name="citation_keywords" content="RAF1"><meta name="citation_keywords" content="RASA2"><meta name="citation_keywords" content="RIT1"><meta name="citation_keywords" content="RRAS2"><meta name="citation_keywords" content="SOS1"><meta name="citation_keywords" content="SOS2"><meta name="citation_keywords" content="Noonan Syndrome"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="DC.Title" content="Noonan Syndrome"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="University of Washington, Seattle"><meta name="DC.Contributor" content="Amy E Roberts"><meta name="DC.Date" content="2022/02/17"><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1124/"><meta name="description" content="Noonan syndrome (NS) is characterized by characteristic facies, short stature, congenital heart defect, and developmental delay of variable degree. Other findings can include broad or webbed neck, unusual chest shape with superior pectus carinatum and inferior pectus excavatum, cryptorchidism, varied coagulation defects, lymphatic dysplasias, and ocular abnormalities. Although birth length is usually normal, final adult height approaches the lower limit of normal. Congenital heart disease occurs in 50%-80% of individuals. Pulmonary valve stenosis, often with dysplasia, is the most common heart defect and is found in 20%-50% of individuals. Hypertrophic cardiomyopathy, found in 20%-30% of individuals, may be present at birth or develop in infancy or childhood. Other structural defects include atrial and ventricular septal defects, branch pulmonary artery stenosis, and tetralogy of Fallot. Up to one fourth of affected individuals have mild intellectual disability, and language impairments in general are more common in NS than in the general population."><meta name="og:title" content="Noonan Syndrome"><meta name="og:type" content="book"><meta name="og:description" content="Noonan syndrome (NS) is characterized by characteristic facies, short stature, congenital heart defect, and developmental delay of variable degree. Other findings can include broad or webbed neck, unusual chest shape with superior pectus carinatum and inferior pectus excavatum, cryptorchidism, varied coagulation defects, lymphatic dysplasias, and ocular abnormalities. Although birth length is usually normal, final adult height approaches the lower limit of normal. Congenital heart disease occurs in 50%-80% of individuals. Pulmonary valve stenosis, often with dysplasia, is the most common heart defect and is found in 20%-50% of individuals. Hypertrophic cardiomyopathy, found in 20%-30% of individuals, may be present at birth or develop in infancy or childhood. Other structural defects include atrial and ventricular septal defects, branch pulmonary artery stenosis, and tetralogy of Fallot. Up to one fourth of affected individuals have mild intellectual disability, and language impairments in general are more common in NS than in the general population."><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1124/"><meta name="og:site_name" content="NCBI Bookshelf"><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbibooks"><meta name="bk-non-canon-loc" content="/books/n/gene/noonan/"><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/"><link rel="stylesheet" href="./Noonan-Syndrome-GeneReviews_files/figpopup.css" type="text/css" media="screen"><link rel="stylesheet" href="./Noonan-Syndrome-GeneReviews_files/books.min.css" type="text/css"><link rel="stylesheet" href="./Noonan-Syndrome-GeneReviews_files/books_print.min.css" type="text/css"><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline} </style><script type="text/javascript" src="./Noonan-Syndrome-GeneReviews_files/jquery.hoverIntent.min.js.download"> </script><script type="text/javascript" src="./Noonan-Syndrome-GeneReviews_files/common.min.js.download"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="./Noonan-Syndrome-GeneReviews_files/book-toc.min.js.download"> </script><script type="text/javascript" src="./Noonan-Syndrome-GeneReviews_files/books.min.js.download"> </script><script type="text/javascript">if (typeof (jQuery) != 'undefined') { (function ($) { $(function () { var min = Math.ceil(1); var max = Math.floor(100000); var randomNum = Math.floor(Math.random() * (max - min)) + min; var surveyUrl = "/projects/Gene/portal/surveys/seqdbui-survey.js?rando=" + randomNum.toString(); $.getScript(surveyUrl, function () { try { ncbi.seqDbUISurvey.init(); } catch (err) { console.info(err); } }).fail(function (jqxhr, settings, exception) { console.info('Cannot load survey script', jqxhr); });; }); })(jQuery); };</script>

        <!-- Page meta end -->
    <link rel="shortcut icon" href="https://www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="CE897BB568B655E100000000022101C8.m_5">
<meta name="referrer" content="origin-when-cross-origin"><link type="text/css" rel="stylesheet" href="./Noonan-Syndrome-GeneReviews_files/3964959.css"><link type="text/css" rel="stylesheet" href="./Noonan-Syndrome-GeneReviews_files/3882866.css" media="print"><script async="1" src="./Noonan-Syndrome-GeneReviews_files/analytics.js.download"></script><style type="text/css">
  .term-highlight { font-weight: bold; }
</style></head>
    <body class="book-part" id="ui-ncbiexternallink-1">
        <div class="grid no_max_width">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            
                            <div class="header">
    
    
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container content">
    <div class="document">
        <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. </p></div></div></div>
        <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1124_"><span class="title" itemprop="name">Noonan <span class="term-highlight">Syndrome</span></span></h1><div class="contrib half_rhythm"><span itemprop="author">Amy E Roberts</span>, MD<div class="affiliation small">Cardiovascular Genetics<br>Boston Children's Hospital<br>Boston, Massachusetts<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.notsobhc.oidrac@strebor.yma" class="oemail">gro.notsobhc.oidrac@strebor.yma</a></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">November 15, 2001</span>; Last Revision: <span itemprop="dateModified">February 17, 2022</span>.</p><p><em>Estimated reading time: 1 hour</em></p></div><div class="body-content whole_rhythm" itemprop="text"><div id="noonan.Summary" itemprop="description"><h2 id="_noonan_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Noonan <span class="term-highlight">syndrome</span> (NS) is characterized by characteristic facies, short stature, congenital heart defect, and developmental delay of variable degree. Other findings can include broad or webbed neck, unusual chest shape with superior pectus carinatum and inferior pectus excavatum, cryptorchidism, varied coagulation defects, lymphatic dysplasias, and ocular abnormalities. Although birth length is usually normal, final adult height approaches the lower limit of normal. Congenital heart disease occurs in 50%-80% of individuals. Pulmonary valve stenosis, often with dysplasia, is the most common heart defect and is found in 20%-50% of individuals. Hypertrophic cardiomyopathy, found in 20%-30% of individuals, may be present at birth or develop in infancy or childhood. Other structural defects include atrial and ventricular septal defects, branch pulmonary artery stenosis, and tetralogy of Fallot. Up to one fourth of affected individuals have mild intellectual disability, and language impairments in general are more common in NS than in the general population.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of Noonan is established in a proband with suggestive findings and a heterozygous pathogenic variant in <i>BRAF</i>, <i>KRAS</i>, <i>MAP2K1</i>, <i>MRAS</i>, <i>NRAS</i>, <i>PTPN11</i>, <i>RAF1</i>, <i>RASA2</i>, <i>RIT1</i>, <i>RRAS2</i>, <i>SOS1</i>, or <i>SOS2</i> or either a heterozygous variant or biallelic pathogenic variants in <i>LZTR1</i> identified by molecular genetic testing. Several additional genes associated with a Noonan <span class="term-highlight">syndrome</span>-like phenotype in fewer than ten individuals have been identified.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Cardiovascular anomalies in NS are usually treated as in the general population. Developmental disabilities are addressed by early intervention programs and individualized education strategies. Treatment for serious bleeding is guided by knowledge of the specific factor deficiency or platelet aggregation anomaly. Growth hormone (GH) treatment increases growth velocity. Standard treatment for juvenile myelomonocytic leukemia (JMML) and other malignancies, feeding difficulties, ADHD, behavioral problems, cryptorchidism in males, renal anomalies&nbsp;/ hydronephrosis, strabismus, hearing loss, and Chiari malformation.</p><p><i>Surveillance:</i> At each visit: measurement of growth parameters; evaluation of nutritional status in infants and toddlers; monitor for evidence of new neurologic manifestations (chronic headache, neck pain, changes in tone, dizziness, or obstructive sleep apnea); monitor developmental progress; assessment of behavioral issues, as age appropriate; skin examination. Annually in childhood or as clinically indicated: ophthalmology and audiology evaluations.</p><ul><li class="half_rhythm"><div>In children age &lt;5 years: if initial cardiac evaluation is normal, at least annual cardiac evaluations until age 5 years.</div></li><li class="half_rhythm"><div>In children age &gt;5 years through adulthood, cardiac evaluation at least every 5 years, or as clinically indicated.</div></li><li class="half_rhythm"><div>Prior to any surgical procedure or in those with clinical bleeding: assessment of bleeding history, CBC with differential, and consideration of measurement of coagulation factors.</div></li><li class="half_rhythm"><div>For those with pathogenic <i>PTPN11</i> or <i>KRAS</i> variants: consider physical examination with assessment of spleen size &amp; CBC every 3-6 months until age 5 years to assess for concerns about JMML/malignancy.</div></li></ul><p><i>Agents/circumstances to avoid</i>: Aspirin therapy should be avoided because it may exacerbate a bleeding diathesis.</p><p><i>Pregnancy management</i>: Consider referral to an adult congenital heart program for peripartum evaluation and management; consider a hematology referral if the affected pregnant woman has a history of bleeding abnormalities and/or has not undergone previous screening for coagulopathy.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>NS is most often inherited in an autosomal dominant manner. While many individuals with autosomal dominant NS have a <i>de nov</i>o pathogenic variant, an affected parent is recognized in 30%-75% of families. The risk to sibs of a proband with autosomal dominant NS depends on the genetic status of the parents: if a parent is affected, the risk is 50%; when the parents are clinically unaffected, the risk to the sibs of a proband appears to be low (&lt;1%). Each child of an individual with autosomal dominant NS has a 50% chance of inheriting the pathogenic variant.</p><p>NS caused by pathogenic variants in <i>LZTR1</i> can be inherited in either an autosomal dominant or an autosomal recessive manner. The parents of an individual with autosomal recessive NS are typically heterozygotes (i.e., have one <i>LZTR1</i> pathogenic variant), and may either be asymptomatic or have mild features of NS. If both parents are heterozygous for one <i>LZTR1</i> pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of having one <i>LZTR1</i> pathogenic variant (which can be associated with mild NS features), and a 25% chance of being unaffected and not a carrier.</p><p>Prenatal testing and preimplantation genetic testing are possible if the NS-related pathogenic variant(s) have been identified in an affected family member.</p></div></div><div id="noonan.Diagnosis"><h2 id="_noonan_Diagnosis_">Diagnosis</h2><p>No consensus clinical diagnostic criteria for Noonan <span class="term-highlight">syndrome</span> have been published. Diagnostic scoring systems, most recently published in <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.van_der_burgt.2007.4" role="button" aria-expanded="false" aria-haspopup="true">van der Burgt [2007]</a> and embedded in the <a href="https://rasopathiesnet.org/wp-content/uploads/2014/01/265_Noonan_Guidelines.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">management guidelines</a> developed by DYSCERNE in the United Kingdom [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF86" role="button" aria-expanded="false" aria-haspopup="true">Noonan <span class="term-highlight">Syndrome</span> Guideline Development Group 2010</a>], have been proposed but have not been used extensively in North America.</p><div id="noonan.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Noonan <span class="term-highlight">syndrome</span> (NS) <b>should be suspected</b> in individuals with the following clinical, laboratory, and family history findings.</p><p>
<b>Clinical findings</b>
</p><ul><li class="half_rhythm"><div class="half_rhythm">Characteristic facies. The facial appearance of NS shows considerable change with age, being most striking in young and middle childhood, and most subtle in adulthood. Key features found regardless of age include the following:</div><ul><li class="half_rhythm"><div>Low-set, posteriorly rotated ears with fleshy helices</div></li><li class="half_rhythm"><div>Vivid blue or blue-green irises</div></li><li class="half_rhythm"><div>Widely spaced and downslanted palpebral fissures</div></li><li class="half_rhythm"><div>Epicanthal folds</div></li><li class="half_rhythm"><div>Fullness or droopiness of the upper eyelids (ptosis)</div></li></ul><div class="half_rhythm"><b>Note:</b> See the National Human Genome Research Institute (NHGRI) <a href="https://research.nhgri.nih.gov/atlas/condition/noonan-syndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Atlas of Human Malformation Syndromes</a> (scroll to <b>ATLAS IMAGES</b>) for photographs of individuals with Noonan <span class="term-highlight">syndrome</span> from diverse ethnic backgrounds.</div></li><li class="half_rhythm"><div class="half_rhythm">Short stature for sex and family background</div></li><li class="half_rhythm"><div class="half_rhythm">Congenital heart defects, most commonly pulmonary valve stenosis, atrial septal defect, and/or hypertrophic cardiomyopathy</div></li><li class="half_rhythm"><div class="half_rhythm">Developmental delay of variable degree</div></li><li class="half_rhythm"><div class="half_rhythm">Broad or webbed neck</div></li><li class="half_rhythm"><div class="half_rhythm">Unusual chest shape with superior pectus carinatum and inferior pectus excavatum</div></li><li class="half_rhythm"><div class="half_rhythm">Widely spaced nipples</div></li><li class="half_rhythm"><div class="half_rhythm">Cryptorchidism in males</div></li><li class="half_rhythm"><div class="half_rhythm">Lymphatic dysplasia of the lungs, intestines, and/or lower extremities</div></li></ul><p><b>Suggestive laboratory findings.</b> Coagulation defects:</p><ul><li class="half_rhythm"><div>Coagulation screens (e.g., prothrombin time, activated partial thromboplastin time, platelet count, and platelet aggregation testing) may show abnormalities.</div></li><li class="half_rhythm"><div>Specific testing should identify the particular coagulation defect, such as von Willebrand disease, thrombocytopenia, varied coagulation factor defects (factors V, VIII, XI, XII, protein C), and platelet dysfunction.</div></li></ul><p><b>Family history</b> is consistent with autosomal dominant (e.g., affected males and females in multiple generations) or ‒ rarely ‒ autosomal recessive inheritance (see <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Genetic_Counseling">Genetic Counseling</a>). Absence of a known family history of Noonan <span class="term-highlight">syndrome</span> does not preclude the diagnosis.</p></div><div id="noonan.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The molecular diagnosis of NS <b>is established</b> in a proband with suggestive findings and a heterozygous pathogenic (or likely pathogenic) variant in one of the genes listed in <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-ob="figobnoonanTmoleculargenetictestingused">Table 1</a> or biallelic pathogenic (or likely pathogenic) variants in <i>LZTR1</i>.</p><p>Note: (1) Per ACMG/AMP variant interpretation guidelines, the terms "pathogenic variant" and "likely pathogenic variant" are synonymous in a clinical setting, meaning that both are considered diagnostic and can be used for clinical decision making [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.richards.2015.405" role="button" aria-expanded="false" aria-haspopup="true">Richards et al 2015</a>]. Reference to "pathogenic variants" in this section is understood to include likely pathogenic variants. (2) The identification of variant(s) of uncertain significance cannot be used to confirm or rule out the diagnosis. (3) As up to 20% of individuals meeting the proposed clinical diagnostic criteria [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.van_der_burgt.2007.4" role="button" aria-expanded="false" aria-haspopup="true">van der Burgt 2007</a>] for NS do not have an identifiable molecular genetic etiology, nondiagnostic genetic testing does not rule out the diagnosis.</p><p>Molecular genetic testing approaches can include a combination of <b>gene-targeted testing</b> (multigene panel) and <b>comprehensive</b>
<b>genomic testing</b> (exome sequencing or genome sequencing) depending on the phenotype.</p><p>Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing does not. Individuals with the distinctive findings described in <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Option_1">Option 1</a>), whereas those in whom the diagnosis of Noonan <span class="term-highlight">syndrome</span> has not been considered are more likely to be diagnosed using genomic testing (see <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Option_2">Option 2</a>).</p><div id="noonan.Option_1"><h4>Option 1</h4><p>When the phenotypic findings suggest the diagnosis of Noonan <span class="term-highlight">syndrome</span>, molecular genetic testing approaches usually include the use of a multigene panel. A <b>Noonan <span class="term-highlight">syndrome</span></b>
<b>multigene panel</b> that includes some or all of the genes listed in <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-ob="figobnoonanTmoleculargenetictestingused">Table 1</a> and other genes of interest (see <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests. Since Noonan <span class="term-highlight">syndrome</span> occurs through a gain-of-function mechanism and large intragenic deletions or duplications have not been reported, testing for intragenic deletions or duplications is unlikely to result in a diagnosis; however, rare cases have been reported for some genes (see <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-ob="figobnoonanTmoleculargenetictestingused">Table 1</a>).</p><p>For an introduction to multigene panels click <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p>Note: <b>Serial single-gene testing</b> can be considered if panel testing is not feasible. Approximately 50% of individuals with NS have a pathogenic missense variant in <i>PTPN11</i>; therefore, single-gene testing starting with <i>PTPN11</i> would be the next best first test. Appropriate serial single-gene testing if <i>PTPN11</i> testing is not diagnostic can be determined by the individual's phenotype (e.g., <i>RIT1</i> if there is hypertrophic cardiomyopathy, <i>LZTR1</i> if autosomal recessive inheritance is suspected); however, continued sequential single-gene testing is not recommended as it is less efficient and more costly than panel testing.</p></div><div id="noonan.Option_2"><h4>Option 2</h4><p>When the diagnosis of Noonan <span class="term-highlight">syndrome</span> has not been considered because an individual has atypical phenotypic features or if some but not all characteristic phenotypic features are present (e.g., a "Noonan-like" phenotype), <b>comprehensive genomic testing,</b> which does not require the clinical to determine which gene is likely involved, may be used. <b>Exome sequencing</b> is most commonly used; <b>genome sequencing</b> is also possible.</p><p>For an introduction to comprehensive genomic testing click <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="noonan.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Noonan <span class="term-highlight">Syndrome</span> (NS)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&nbsp;<sup>1,&nbsp;2</sup></th><th id="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of NS Attributed to Pathogenic Variants in Gene</th><th id="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&nbsp;<sup>3</sup> Detected by Method</th></tr><tr><th headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3" id="hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&nbsp;<sup>4</sup></th><th headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3" id="hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted deletion/duplication analysis&nbsp;<sup>5</sup></th></tr></thead><tbody><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>BRAF</i>
</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&lt;2%&nbsp;<sup>6</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&nbsp;<sup>7</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>KRAS</i>
</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&lt;5%&nbsp;<sup>8</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&nbsp;<sup>7</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>LZTR1</i>
</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~8%&nbsp;<sup>9</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&nbsp;<sup>7</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>MAP2K1</i>
</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&lt;2%&nbsp;<sup>10</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&nbsp;<sup>7</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>MRAS</i>
</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&lt;1%&nbsp;<sup>11</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&nbsp;<sup>7</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>NRAS</i>
</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&lt;1%&nbsp;<sup>12</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&nbsp;<sup>7</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>PTPN11</i>
</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%&nbsp;<sup>13</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nearly 100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rare duplication,&nbsp;<sup>14</sup> diagnosis of NS questioned&nbsp;<sup>15</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>RAF1</i>
</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%&nbsp;<sup>16</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nearly 100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 reported case w/a duplication,&nbsp;<sup>17</sup> diagnosis of NS questioned&nbsp;<sup>15</sup>; 1 reported case of a deletion&nbsp;<sup>18</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>RASA2</i>
</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&nbsp;<sup>19</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&nbsp;<sup>7</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>RIT1</i>
</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%&nbsp;<sup>16</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&nbsp;<sup>7</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>RRAS2</i>
</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&lt;1%&nbsp;<sup>20</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&nbsp;<sup>7</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>SOS1</i>
</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%-13%&nbsp;<sup>21</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&nbsp;<sup>7</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>SOS2</i>
</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~4%&nbsp;<sup>22</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&nbsp;<sup>7</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Others&nbsp;<sup>23</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="noonan.TF.1.1"><p class="no_margin">Genes are listed in alphabetic order.</p></div></dd><dt>2. </dt><dd><div id="noonan.TF.1.2"><p class="no_margin">See <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/#noonan.molgen.TA">Table A. Genes and Databases</a> for chromosome locus and protein</p></div></dd><dt>3. </dt><dd><div id="noonan.TF.1.3"><p class="no_margin">See <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Molecular_Genetics">Molecular Genetics</a> for information on variants detected in these genes</p></div></dd><dt>4. </dt><dd><div id="noonan.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="noonan.TF.1.5"><p class="no_margin">Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include a range of techniques such as quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="noonan.TF.1.6"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.sarkozy.2009.695" role="button" aria-expanded="false" aria-haspopup="true">Sarkozy et al [2009]</a>
</p></div></dd><dt>7. </dt><dd><div id="noonan.TF.1.7"><p class="no_margin">No data on detection rate of gene-targeted deletion/duplication analysis are available.</p></div></dd><dt>8. </dt><dd><div id="noonan.TF.1.8"><p class="no_margin"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.schubbert.2006.331" role="button" aria-expanded="false" aria-haspopup="true">Schubbert et al [2006]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.brasil.2010.425" role="button" aria-expanded="false" aria-haspopup="true">Brasil et al [2010]</a></p></div></dd><dt>9. </dt><dd><div id="noonan.TF.1.9"><p class="no_margin"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.chen.2014b.11473" role="button" aria-expanded="false" aria-haspopup="true">Chen et al [2014b]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.yamamoto.2015.413" role="button" aria-expanded="false" aria-haspopup="true">Yamamoto et al [2015]</a></p></div></dd><dt>10. </dt><dd><div id="noonan.TF.1.10"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.nava.2007.763" role="button" aria-expanded="false" aria-haspopup="true">Nava et al [2007]</a>
</p></div></dd><dt>11. </dt><dd><div id="noonan.TF.1.11"><p class="no_margin"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.higgins.2017.e91225" role="button" aria-expanded="false" aria-haspopup="true">Higgins et al [2017]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.motta.2019.1007" role="button" aria-expanded="false" aria-haspopup="true">Motta et al [2019]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.suzuki.2019.1628" role="button" aria-expanded="false" aria-haspopup="true">Suzuki et al [2019]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.pires.2021.3099" role="button" aria-expanded="false" aria-haspopup="true">Pires et al [2021]</a></p></div></dd><dt>12. </dt><dd><div id="noonan.TF.1.12"><p class="no_margin"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.altm_ller.2017.823" role="button" aria-expanded="false" aria-haspopup="true">Altmüller et al [2017]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.garren.2020.195" role="button" aria-expanded="false" aria-haspopup="true">Garren et al [2020]</a></p></div></dd><dt>13. </dt><dd><div id="noonan.TF.1.13"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.tartaglia.2002.1555" role="button" aria-expanded="false" aria-haspopup="true">Tartaglia et al [2002]</a>
</p></div></dd><dt>14. </dt><dd><div id="noonan.TF.1.14"><p class="no_margin"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.shchelochkov.2008.1042" role="button" aria-expanded="false" aria-haspopup="true">Shchelochkov et al [2008]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.graham.2009.2122" role="button" aria-expanded="false" aria-haspopup="true">Graham et al [2009]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.chen.2014a.28" role="button" aria-expanded="false" aria-haspopup="true">Chen et al [2014a]</a></p></div></dd><dt>15. </dt><dd><div id="noonan.TF.1.15"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.lissewski.2015.2685" role="button" aria-expanded="false" aria-haspopup="true">Lissewski et al [2015]</a>
</p></div></dd><dt>16. </dt><dd><div id="noonan.TF.1.16"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.aoki.2016.33" role="button" aria-expanded="false" aria-haspopup="true">Aoki et al [2016]</a>
</p></div></dd><dt>17. </dt><dd><div id="noonan.TF.1.17"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.luo.2012.1918" role="button" aria-expanded="false" aria-haspopup="true">Luo et al [2012]</a>
</p></div></dd><dt>18. </dt><dd><div id="noonan.TF.1.18"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.sana.2014.2069" role="button" aria-expanded="false" aria-haspopup="true">Sana et al [2014]</a>
</p></div></dd><dt>19. </dt><dd><div id="noonan.TF.1.19"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.chen.2014b.11473" role="button" aria-expanded="false" aria-haspopup="true">Chen et al [2014b]</a>
</p></div></dd><dt>20. </dt><dd><div id="noonan.TF.1.20"><p class="no_margin"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.capri.2019.1223" role="button" aria-expanded="false" aria-haspopup="true">Capri et al [2019]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.niihori.2019.1233" role="button" aria-expanded="false" aria-haspopup="true">Niihori et al [2019]</a></p></div></dd><dt>21. </dt><dd><div id="noonan.TF.1.21"><p class="no_margin">Approximately 16%-20% of individuals with a clinical diagnosis of Noonan <span class="term-highlight">syndrome</span> who do not have an identified <i>PTPN11</i> pathogenic variant are found to have an <i>SOS1</i> pathogenic variant [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.roberts.2007.70" role="button" aria-expanded="false" aria-haspopup="true">Roberts et al 2007</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.tartaglia.2007.75" role="button" aria-expanded="false" aria-haspopup="true">Tartaglia et al 2007</a>].</p></div></dd><dt>22. </dt><dd><div id="noonan.TF.1.22"><p class="no_margin"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.chen.2014b.11473" role="button" aria-expanded="false" aria-haspopup="true">Chen et al [2014b]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.cordeddu.2015.1080" role="button" aria-expanded="false" aria-haspopup="true">Cordeddu et al [2015]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.yamamoto.2015.413" role="button" aria-expanded="false" aria-haspopup="true">Yamamoto et al [2015]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.lissewski.2021.51" role="button" aria-expanded="false" aria-haspopup="true">Lissewski et al [2021]</a></p></div></dd><dt>23. </dt><dd><div id="noonan.TF.1.23"><p class="no_margin">Recent reports have implicated additional genes associated with a Noonan <span class="term-highlight">syndrome</span>-like phenotype in fewer than ten individuals each, including <i>RRAS</i> (2 probands) [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.flex.2014.4315" role="button" aria-expanded="false" aria-haspopup="true">Flex et al 2014</a>] and <i>A2ML1</i> (3 probands) [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.vissers.2015.317" role="button" aria-expanded="false" aria-haspopup="true">Vissers et al 2015</a>].</p></div></dd></dl></div></div></div></div></div></div><div id="noonan.Clinical_Characteristics"><h2 id="_noonan_Clinical_Characteristics_">Clinical Characteristics</h2><div id="noonan.Clinical_Description"><h3>Clinical Description</h3><p>To date, including those with a clinical and a molecular genetic diagnosis and with an estimated incidence of 1:1000-1:2500, several thousand individuals have been identified with Noonan <span class="term-highlight">syndrome</span> (NS) [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.roberts.2013.333" role="button" aria-expanded="false" aria-haspopup="true">Roberts et al 2013</a>]. The following description of the phenotypic features associated with this condition is based on these reports.</p><div id="noonan.T.noonan_syndrome_frequency_of_se" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Noonan <span class="term-highlight">Syndrome</span>: Frequency of Select Features</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.noonan_syndrome_frequency_of_se/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.T.noonan_syndrome_frequency_of_se_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Feature</th><th id="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% of Persons<br>w/Feature</th><th id="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Eye anomalies</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">95%</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Short stature</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%-70%</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For age, sex, &amp; family background</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypotonia</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Majority</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Can contribute to feeding problems, speech articulation issues, &amp; delayed attainment of gross motor milestones</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Joint hyperextensibility</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Majority</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pectus anomaly</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Majority</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Characteristic pectus deformity of the chest: pectus carinatum superiorly &amp; pectus excavatum inferiorly</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cryptorchidism in males</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60%-80%</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Congenital heart disease</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%-80%</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25%-71% of affected persons have pulmonary valve stenosis, often w/pulmonary valve dysplasia.</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hearing loss</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40%</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">May be sensorineural, conductive, or mixed</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypertrophic cardiomyopathy</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%-29%</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Half of those w/hypertrophic cardiomyopathy are diagnosed by age 6 mos.</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Learning disability</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25%</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">~10%-15% of those w/NS require special education.</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Intellectual disability&nbsp;<sup>1</sup></td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6%-23%</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Renal anomalies</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11%</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Most commonly dilatation of the renal pelvis</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Abnormal bleeding or bruising</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bleeding: 6%-10%; bruising: majority</td><td headers="hd_h_noonan.T.noonan_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="noonan.TF.2.1"><p class="no_margin">Defined as IQ &lt;70</p></div></dd></dl></div></div></div><p><b>Prenatal features.</b> Advanced paternal age has been observed in cohorts with simplex NS. Common perinatal findings [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.stuurman.2019.654" role="button" aria-expanded="false" aria-haspopup="true">Stuurman et al 2019</a>]:</p><ul><li class="half_rhythm"><div>Polyhydramnios</div></li><li class="half_rhythm"><div>Lymphatic dysplasia including increased distended jugular lymphatic sacs, nuchal translucency, cystic hygroma, pleural effusion, and ascites</div></li><li class="half_rhythm"><div>Relative macrocephaly</div></li><li class="half_rhythm"><div>Cardiac and renal anomalies</div></li></ul><p>In chromosomally normal fetuses with increased nuchal translucency, it is estimated that 3%-15% have <i>PTPN11</i>-associated NS [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.stuurman.2019.654" role="button" aria-expanded="false" aria-haspopup="true">Stuurman et al 2019</a>].</p><p><b>Growth.</b> Birth weight is usually normal, although edema may cause a transient increase. Infants with NS frequently have feeding difficulties. This period of failure to thrive is self limited, although poor weight gain may persist for up to 18 months.</p><p>Length at birth is usually normal. Postnatal growth failure is often obvious from the first year of life [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.seo.2018.176" role="button" aria-expanded="false" aria-haspopup="true">Seo &amp; Yoo 2018</a>]. Mean height then follows the third centile from ages two to four years until puberty, when below-average growth velocity and an attenuated adolescent growth spurt tend to occur. As bone maturity is usually delayed, prolonged growth into the 20s is possible.</p><p>Final adult height approaches the lower limit of normal: 161-167 cm in males and 150-155 cm in females. Growth curves have been developed from these cross-sectional retrospective data. One study suggests that 30% of affected individuals have height within the normal adult range, while more than 50% of females and nearly 40% of males have an adult height below the third centile [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.seo.2018.176" role="button" aria-expanded="false" aria-haspopup="true">Seo &amp; Yoo 2018</a>].</p><p>In many affected persons, decreased IGF-I- and IGF-binding protein 3, together with low responses to provocation, suggest impaired growth hormone release or disturbance of the growth hormone&nbsp;/ insulin-like growth factor I axis. Mild growth hormone resistance related to a post-receptor signaling defect (which may be partially compensated for by elevated growth hormone secretion) is reported in individuals with NS and a <i>PTPN11</i> pathogenic variant [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.seo.2018.176" role="button" aria-expanded="false" aria-haspopup="true">Seo &amp; Yoo 2018</a>].</p><p>Growth hormone (GH) therapy has been used in individuals with NS (see <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Management">Management</a>):</p><ul><li class="half_rhythm"><div>In Europe, GH treatment is the standard of care for children with abnormalities of the GH-IGF-I axis and could be used when GH physiology is normal.</div></li><li class="half_rhythm"><div>Short- and long-term studies of GH treatment have been published [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.ogawa.2004.61" role="button" aria-expanded="false" aria-haspopup="true">Ogawa et al 2004</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.osio.2005.1232" role="button" aria-expanded="false" aria-haspopup="true">Osio et al 2005</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.noordam.2007.24" role="button" aria-expanded="false" aria-haspopup="true">Noordam 2007</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.noordam.2008.203" role="button" aria-expanded="false" aria-haspopup="true">Noordam et al 2008</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.romano.2009.2338" role="button" aria-expanded="false" aria-haspopup="true">Romano et al 2009</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.rohrer.2020.380" role="button" aria-expanded="false" aria-haspopup="true">Rohrer et al 2020</a>] and demonstrate a consistent and significant increase in height velocity in children with Noonan <span class="term-highlight">syndrome</span> who have been treated.</div></li><li class="half_rhythm"><div>The increase in height standard deviation (SD) varies from 0.6 to 1.8 SD and may depend on age at start of treatment, duration of study, age at onset of puberty, and/or GH sensitivity [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.seo.2018.176" role="button" aria-expanded="false" aria-haspopup="true">Seo &amp; Yoo 2018</a>].</div></li><li class="half_rhythm"><div>Studies have shown that children with prepubertal NS growth hormone deficiency have increased their growth rate with GH therapy at a rate equivalent to girls with Turner <span class="term-highlight">syndrome</span> but at a lower rate than that seen in idiopathic GH deficiency [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.lee.2015.17" role="button" aria-expanded="false" aria-haspopup="true">Lee et al 2015</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.zavras.2015.71" role="button" aria-expanded="false" aria-haspopup="true">Zavras et al 2015</a>].</div></li></ul><p><b>Cardiovascular.</b> Significant bias in the frequency of congenital heart disease may exist because many clinicians have in the past required the presence of cardiac anomalies for diagnosis of NS. The frequency of congenital heart disease is estimated at between 50% and 80%.</p><ul><li class="half_rhythm"><div><b>Pulmonary valve</b>
<b>stenosis,</b> often with dysplasia, is the most common anomaly in NS, found in 25%-71% of affected individuals; it may be isolated or associated with other cardiovascular defects.</div></li><li class="half_rhythm"><div><b>Hypertrophic cardiomyopathy</b> is found in 10%-29% of individuals with NS. It usually presents early in life: the median age at diagnosis is five months and more than 50% of individuals with NS and hypertrophic cardiomyopathy are diagnosed by age six months [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.hickey.2011.41" role="button" aria-expanded="false" aria-haspopup="true">Hickey et al 2011</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.wilkinson.2012.442" role="button" aria-expanded="false" aria-haspopup="true">Wilkinson et al 2012</a>].</div></li><li class="half_rhythm"><div><b>Other structural defects</b> frequently observed include atrial septal defects (4%-57%), ventricular septal defects (1%-14%), atrioventricular canal defects (1%-13%), mitral valve abnormalities (2%-17%), aortic coarctation (2%-9%), patent ductus arteriosus (1%-6%), and tetralogy of Fallot (1%-4%) [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.linglart.2020.73" role="button" aria-expanded="false" aria-haspopup="true">Linglart &amp; Gelb 2020</a>].</div></li><li class="half_rhythm"><div><b>An electrocardiographic abnormality</b> is documented in approximately 90% of individuals with NS and may be present without concomitant structural defects. Extreme right axis deviation with superior counterclockwise frontal QRS loop, superior or left axis deviation, left anterior hemiblock, or an RSR' pattern in lead V1 (of no clinical consequence) are common findings [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.sharland.1992.178" role="button" aria-expanded="false" aria-haspopup="true">Sharland et al 1992</a>].</div></li></ul><p><b>Psychomotor development.</b> Early developmental milestones may be delayed, likely in part as a result of the combination of joint hyperextensibility and hypotonia. The average age for sitting unsupported is around ten months and for walking is 21 months [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.pierpont.2016.14" role="button" aria-expanded="false" aria-haspopup="true">Pierpont 2016</a>]. About 50% of school-age children meet diagnostic criteria for a developmental coordination disorder [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.lee.2005a.35" role="button" aria-expanded="false" aria-haspopup="true">Lee et al 2005a</a>] and impaired manual dexterity is significantly correlated with verbal and nonverbal intellectual functioning [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.pierpont.2015.385" role="button" aria-expanded="false" aria-haspopup="true">Pierpont et al 2015</a>].</p><p>Most school-age children perform well in a normal educational setting, but 25% have learning disabilities [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.lee.2005a.35" role="button" aria-expanded="false" aria-haspopup="true">Lee et al 2005a</a>] and 10%-15% require special education [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.van_der_burgt.1999.707" role="button" aria-expanded="false" aria-haspopup="true">van der Burgt et al 1999</a>]. Intellectual abilities are in general mildly lowered in children with NS. IQ scores below 70 are seen in 6%-23% across studies [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.pierpont.2015.385" role="button" aria-expanded="false" aria-haspopup="true">Pierpont et al 2015</a>]. Studies conflict with regard to strength in verbal vs nonverbal performance and no clear pattern has emerged [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.pierpont.2015.385" role="button" aria-expanded="false" aria-haspopup="true">Pierpont et al 2015</a>]. There may be a specific cognitive disability, either in verbal or praxic reasoning, requiring a special academic strategy and school placement.</p><p>Articulation deficiency is common (72%) but usually responds well to speech therapy. Language delay may be related to hearing loss, perceptual motor disabilities, or articulation deficiencies. The average age at first words is around 15 months and simple two-word phrases emerge on average from age 31 to 32 months [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.pierpont.2015.385" role="button" aria-expanded="false" aria-haspopup="true">Pierpont et al 2015</a>].</p><p>A study of the language phenotype of children and adults with NS showed that language impairments in general are more common in NS than in the general population and a majority of children (70%) receive speech and language therapy. When language issues are present, there is a higher risk for reading and spelling difficulties [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.pierpont.2015.385" role="button" aria-expanded="false" aria-haspopup="true">Pierpont et al 2015</a>]. Language is significantly correlated with nonverbal cognition, hearing ability, articulation, motor dexterity, and phonologic memory. No specific aspect of language was selectively affected in those with NS.</p><p>There is emerging evidence that impairment in attention and executive functioning is one of the most common neuropsychological challenges for children with NS [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.pierpont.2015.385" role="button" aria-expanded="false" aria-haspopup="true">Pierpont et al 2015</a>]. Studies that rely on screening measures rather than comprehensive diagnostic assessments suggest that children with NS are at heightened risk for autism spectrum disorders; however, further research is needed [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.pierpont.2016.14" role="button" aria-expanded="false" aria-haspopup="true">Pierpont 2016</a>].</p><p><b>Psychological health.</b> Few details of psychological health in Noonan <span class="term-highlight">syndrome</span> are reported. No particular <span class="term-highlight">syndrome</span> of behavioral disability or psychopathology is observed, and self-esteem is comparable to age-related peers [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.lee.2005a.35" role="button" aria-expanded="false" aria-haspopup="true">Lee et al 2005a</a>]. A study of 37 individuals with a molecular genetic diagnosis of Noonan <span class="term-highlight">syndrome</span> demonstrated a higher incidence of emotional dysregulation, irritability, and anxiety symptomatology compared to the general population [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.alfieri.2021.233" role="button" aria-expanded="false" aria-haspopup="true">Alfieri et al 2021</a>]. <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.noonan.a" role="button" aria-expanded="false" aria-haspopup="true">Noonan [2005a]</a> documented problems in a cohort of 51 adults: depression was found in 23%, and occasional substance abuse and bipolar disease were reported. Similar findings were not reported in a large UK cohort followed over many years [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.shaw.2007.128" role="button" aria-expanded="false" aria-haspopup="true">Shaw et al 2007</a>]. In one study of adults with NS, 49% reported that they had been diagnosed and treated for depression and/or anxiety [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.smpokou.2012.3106" role="button" aria-expanded="false" aria-haspopup="true">Smpokou et al 2012</a>].</p><p><b>Genitourinary.</b> Renal abnormalities, generally mild, are present in 11% of individuals with NS. Dilatation of the renal pelvis is most common. Duplex collecting systems, minor rotational anomalies, distal ureteric stenosis, renal hypoplasia, unilateral renal agenesis, unilateral renal ectopia, and bilateral cysts with scarring are reported less commonly.</p><p>Male pubertal development and subsequent fertility may be normal, delayed, or inadequate. Deficient spermatogenesis may be related to cryptorchidism, which is noted in 60%-80% of males; however, a study of male gonadal function identified Sertoli cell dysfunction both in males with cryptorchidism and those with normal testicular descent, suggesting an intrinsic defect leading to hypergonadotropic hypogonadism [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.moniez.2018.409" role="button" aria-expanded="false" aria-haspopup="true">Moniez et al 2018</a>].</p><p>Puberty may be delayed in females, with a mean age at menarche of 14.6±1.17 years. Normal fertility is the rule.</p><p><b>Facial features.</b> Differences in facial appearance, albeit subtle at certain ages, are a key clinical feature:</p><ul><li class="half_rhythm"><div><b>In the neonate,</b> tall forehead, widely spaced eyes with downslanted palpebral fissures, low-set, posteriorly rotated ears with a thickened helix, a deeply grooved philtrum with high, wide peaks to the vermilion border of the upper lip, and a short neck with excess nuchal skin and low posterior hairline are found.</div></li><li class="half_rhythm"><div><b>In infancy,</b> eyes are prominent, with horizontal palpebral fissures, widely spaced eyes, and full or ptotic upper eyelids. The nose has a depressed nasal bridge, wide base, and bulbous tip.</div></li><li class="half_rhythm"><div><b>In childhood,</b> facial appearance is often lacking in affect or expression, as in an individual with a myopathy.</div></li><li class="half_rhythm"><div><b>By adolescence,</b> facial shape is an inverted triangle, wide at the forehead and tapering to a pointed chin. Eyes are less prominent and features are sharper. The neck lengthens, accentuating skin webbing or prominence of the trapezius muscle.</div></li><li class="half_rhythm"><div><b>In the older adult,</b> nasolabial folds are prominent, and the skin appears transparent and wrinkled.</div></li></ul><p>
<b>Skeletal features</b>
</p><ul><li class="half_rhythm"><div>Thoracic scoliosis is reported in 13%-30% of individuals diagnosed at a mean age of nine years.</div></li><li class="half_rhythm"><div>Estimates of the frequency of the characteristic appearance of the chest (superior pectus carinatum and inferior pectus excavatum with a broad chest and increased inter-nipple distance) range from 28% to 95% [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.rodr_guez.2020.732" role="button" aria-expanded="false" aria-haspopup="true">Rodríguez et al 2020</a>].</div></li><li class="half_rhythm"><div>Vertebral defects have also been reported.</div></li><li class="half_rhythm"><div>Reported upper limb anomalies include cubitus valgus, radioulnar synostosis, brachydactyly, and fifth finger clinodactyly.</div></li><li class="half_rhythm"><div>Common maxillofacial features include micrognathia, high arched palate, and dental crowding [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.rodr_guez.2020.732" role="button" aria-expanded="false" aria-haspopup="true">Rodríguez et al 2020</a>].</div></li><li class="half_rhythm"><div>Small studies have suggested lower bone mineral density in children and osteopenia in adults [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.fowlkes.2021.116060" role="button" aria-expanded="false" aria-haspopup="true">Fowlkes et al 2021</a>].</div></li><li class="half_rhythm"><div>Multiple giant cell lesions of the jaw, joints (pigmented villonodular synovitis), and/or soft tissue have been reported in association with <i>PTPN11</i>-, <i>SOS1</i>-, and <i>RAF1</i>-associated cases of Noonan <span class="term-highlight">syndrome</span> [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.miri.2018.7698052" role="button" aria-expanded="false" aria-haspopup="true">Miri et al 2018</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.rodr_guez.2020.732" role="button" aria-expanded="false" aria-haspopup="true">Rodríguez et al 2020</a>].</div></li></ul><p><b>Bleeding diathesis.</b> Most persons with NS have a history of abnormal bleeding or bruising. Early studies reported that about one third of all individuals with NS have one or more coagulation defects, with subsequent studies suggesting a lower rate of coagulopathy [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.derbent.2010.2768" role="button" aria-expanded="false" aria-haspopup="true">Derbent et al 2010</a>]. The coagulopathy may manifest as severe surgical hemorrhage, clinically mild bruising, or laboratory abnormalities with no clinical consequences. A variety of small studies have shown that while 50%-89% of those with NS have either a history of bleeding and/or abnormal hemostatic lab results, only 10%-42% have both (reviewed in <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.briggs.2012.167" role="button" aria-expanded="false" aria-haspopup="true">Briggs &amp; Dickerman [2012]</a>). A study of 70 individuals with NS who had not had preoperative evaluation for coagulopathy demonstrated a 6.2% risk of perioperative bleeding complications [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.briggs.2020.154" role="button" aria-expanded="false" aria-haspopup="true">Briggs et al 2020</a>].</p><p><b>Lymphatic.</b> Varied lymphatic abnormalities are described in individuals with NS. They may be localized or widespread, prenatal, and/or postnatal. Dorsal limb (top of the foot and back of the hand) lymphedema is most common. Less common findings include: intestinal, pulmonary, or testicular lymphangiectasia; chylous effusions of the pleural space and/or peritoneum; and localized lymphedema of the scrotum or vulva.</p><p><b>Ocular.</b> Ocular abnormalities including ptosis, strabismus, refractive errors, amblyopia, and nystagmus occur in up to 95% of affected individuals. Anterior segment and fundus changes are less common. There are case reports of keratoconus and Axenfeld anomaly [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.lee.2014.1171" role="button" aria-expanded="false" aria-haspopup="true">Lee &amp; Sakhalkar 2014</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.guerin.2015.403" role="button" aria-expanded="false" aria-haspopup="true">Guerin et al 2015</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.van_trier.2018.1293" role="button" aria-expanded="false" aria-haspopup="true">van Trier et al 2018</a>].</p><p><b>Ears/hearing.</b> Hearing impairment has an estimated incidence of 40%. Some individuals have sensorineural hearing loss, others have a secondary conductive hearing loss due to chronic otitis media or middle ear effusion, and some have mixed conductive and sensorineural hearing loss [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.van_nierop.2017.228" role="button" aria-expanded="false" aria-haspopup="true">van Nierop et al 2017</a>].</p><p><b>Dermatologic.</b> Skin differences, particularly follicular keratosis over extensor surfaces and face, are relatively common and may occasionally be as severe as those found in <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/cfc/">cardiofaciocutaneous <span class="term-highlight">syndrome</span></a> (see <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Differential_Diagnosis">Differential Diagnosis</a>).</p><p>Café au lait spots and lentigines are described in NS more frequently than in the general population (see Noonan <span class="term-highlight">syndrome</span> with multiple lentigines discussion in <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Genetically_Related_Allelic_Disor">Genetically Related Disorders</a>).</p><p>
<b>Other</b>
</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Arnold-Chiari I malformation.</b> Eleven cases of Arnold-Chiari malformation have been reported in the medical literature; the true incidence in NS is not known [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.smpokou.2012.3106" role="button" aria-expanded="false" aria-haspopup="true">Smpokou et al 2012</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.keh.2013.749" role="button" aria-expanded="false" aria-haspopup="true">Keh et al 2013</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.mitsuhara.2014.6" role="button" aria-expanded="false" aria-haspopup="true">Mitsuhara et al 2014</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.zarate.2014.np13" role="button" aria-expanded="false" aria-haspopup="true">Zarate et al 2014</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.ejarque.2015.408" role="button" aria-expanded="false" aria-haspopup="true">Ejarque et al 2015</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Hepatosplenomegaly</b> is frequent; the cause is likely related to subclinical myelodysplasia.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Juvenile myelomonocytic leukemia (JMML).</b> The most common hematologic disorder in NS is transient myeloproliferative disorder, typically diagnosed in the neonatal period or early infancy. An estimated 10% of these cases progress to JMML [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.niemeyer.2014.1653" role="button" aria-expanded="false" aria-haspopup="true">Niemeyer 2014</a>]. Individuals with Noonan <span class="term-highlight">syndrome</span> and a germline pathogenic variant in <i>PTPN11</i> have a predisposition to this unusual childhood leukemia. In general, JMML in Noonan <span class="term-highlight">syndrome</span> runs a more benign course. The associated variants are different from the somatic pathogenic variants in <i>PTPN11</i>-associated JMML, which ‒ when present as germline variants ‒ are associated with neonatal-lethal NS [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.masonsuares.2017.509" role="button" aria-expanded="false" aria-haspopup="true">Mason-Suares et al 2017</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Other malignancies.</b> One study of individuals with Noonan <span class="term-highlight">syndrome</span> caused by a pathogenic variant in <i>PTPN11</i> supports a threefold increased risk of malignancy [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.jongmans.2011.870" role="button" aria-expanded="false" aria-haspopup="true">Jongmans et al 2011</a>].</div><ul><li class="half_rhythm"><div>Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are found at higher frequency in Noonan <span class="term-highlight">syndrome</span> than in the general population [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.hasle.2009.8" role="button" aria-expanded="false" aria-haspopup="true">Hasle 2009</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.jongmans.2011.870" role="button" aria-expanded="false" aria-haspopup="true">Jongmans et al 2011</a>].</div></li><li class="half_rhythm"><div>Solid tumors, such as rhabdomyosarcoma and neuroblastoma, are described [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.denayer.2010.242" role="button" aria-expanded="false" aria-haspopup="true">Denayer et al 2010</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.jongmans.2010.635" role="button" aria-expanded="false" aria-haspopup="true">Jongmans et al 2010</a>]. Three embryonal rhabdomyosarcomas (ERMS) caused by a germline <i>SOS1</i> pathogenic variant have been reported [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.denayer.2010.242" role="button" aria-expanded="false" aria-haspopup="true">Denayer et al 2010</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.hastings.2010.967" role="button" aria-expanded="false" aria-haspopup="true">Hastings et al 2010</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.jongmans.2010.635" role="button" aria-expanded="false" aria-haspopup="true">Jongmans et al 2010</a>]. One with obstructive jaundice involved the biliary ampulla/duodenum; one the bladder; and one the urachus. Three additional cases of ERMS and NS (of the orbit, vagina, and abdomen) were reported; genotype was not determined [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.khan.1995.743" role="button" aria-expanded="false" aria-haspopup="true">Khan et al 1995</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.jung.2003.330" role="button" aria-expanded="false" aria-haspopup="true">Jung et al 2003</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.moschovi.2007.341" role="button" aria-expanded="false" aria-haspopup="true">Moschovi et al 2007</a>].</div></li><li class="half_rhythm"><div>A recent review of the literature yielded 30 cases of individuals with <i>PTPN11</i>-associated NS yielded 28 cases of brain tumors, 24 of which were low-grade gliomas and glioneuronal tumors [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.lodi.2020.582" role="button" aria-expanded="false" aria-haspopup="true">Lodi et al 2020</a>].</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>Noonan-like&nbsp;/ multiple giant-cell lesion <span class="term-highlight">syndrome</span>.</b> The giant-cell granulomas and bone and joint anomalies in Noonan-like&nbsp;/ multiple giant-cell lesion <span class="term-highlight">syndrome</span> are recognized to be part of the Noonan <span class="term-highlight">syndrome</span> spectrum. They can resemble cherubism (an autosomal dominant disorder caused by pathogenic variants in <i>SH3BP2</i>; see <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/cherubism/">Cherubism</a>), lesions observed in neurofibromatosis (see <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/nf1/">Neurofibromatosis Type 1</a>), or lesions observed in the Ramon <span class="term-highlight">syndrome</span> with juvenile rheumatoid arthritis (polyarticular pigmented villonodular synovitis).</div><div class="half_rhythm">Noonan-like / multiple giant-cell lesion <span class="term-highlight">syndrome</span> is caused by pathogenic variants in <i>PTPN11</i> [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.jafarov.2005.190" role="button" aria-expanded="false" aria-haspopup="true">Jafarov et al 2005</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.wolvius.2006.1289" role="button" aria-expanded="false" aria-haspopup="true">Wolvius et al 2006</a>] and <i>SOS1</i> [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.beneteau.2009.1216" role="button" aria-expanded="false" aria-haspopup="true">Beneteau et al 2009</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.neumann.2009.420" role="button" aria-expanded="false" aria-haspopup="true">Neumann et al 2009</a>]. One family with Noonan-like / multiple giant-cell lesion <span class="term-highlight">syndrome</span> has a <i>PTPN11</i> pathogenic variant that was also reported in Noonan <span class="term-highlight">syndrome</span> without giant-cell lesions [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.tartaglia.2002.1555" role="button" aria-expanded="false" aria-haspopup="true">Tartaglia et al 2002</a>]; thus, additional genetic factors may be necessary for the giant-cell proliferation to occur.</div></li><li class="half_rhythm"><div class="half_rhythm">These multiple giant cell lesions are also recognized in persons with <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/cfc/">cardiofaciocutaneous <span class="term-highlight">syndrome</span></a>, caused by mutation of <i>BRAF</i> and <i>MEK1</i> [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.neumann.2009.420" role="button" aria-expanded="false" aria-haspopup="true">Neumann et al 2009</a>]. Thus, dysregulation of the RAS-MAPK pathway represents the common and basic molecular event predisposing to giant-cell lesion formation, arguing against the existence of Noonan-like / multiple giant-cell lesion <span class="term-highlight">syndrome</span> as a separate entity.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Overall risk of malignancy.</b>
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.kratz.2015.1392" role="button" aria-expanded="false" aria-haspopup="true">Kratz et al [2015]</a> reported on a cohort of 632 individuals with molecularly confirmed NS (inclusive of Noonan <span class="term-highlight">syndrome</span> with multiple lentigines) and found four individuals with JMML, two with brain tumor, two with ALL, and one with neuroblastoma; they calculated a childhood cancer standardized incidence ratio of 8.1 [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.kratz.2015.1392" role="button" aria-expanded="false" aria-haspopup="true">Kratz et al 2015</a>]. Individuals with NS are at an eightfold greater risk of developing a childhood cancer than are those without NS. The overall cancer risk by age 20 years is estimated to be 4% [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.lodi.2020.582" role="button" aria-expanded="false" aria-haspopup="true">Lodi et al 2020</a>].</div><div class="half_rhythm">An international meeting of the American Association for Cancer Research was held to propose consensus surveillance recommendations for RASopathies and other genetic disorders associated with increased childhood cancer risk. Overall, because the cancer risk falls below 5%, routine cancer surveillance was not recommended. However, for those with <i>PTPN11</i> or <i>KRAS</i> variants known to be associated with myeloproliferative disorder or JMML, physical examination every three to six months with spleen size assessment and complete blood count from birth/time of diagnosis to age five years was recommended for consideration ‒ though there is not yet evidence that this strategy leads to survival advantage [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.villani.2017.e83" role="button" aria-expanded="false" aria-haspopup="true">Villani et al 2017</a>].</div></li></ul></div><div id="noonan.Phenotype_Correlations_by_Gene"><h3>Phenotype Correlations by Gene</h3><p>There are no known phenotype correlations for <i>RASA2</i> or <i>RRAS2</i>.</p><div id="noonan.T.noonan_syndrome_phenotype_corre" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Noonan <span class="term-highlight">Syndrome</span> Phenotype Correlations by Gene</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.noonan_syndrome_phenotype_corre/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.T.noonan_syndrome_phenotype_corre_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&nbsp;<sup>1</sup></th><th id="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2" colspan="5" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Phenotypic Feature</th></tr><tr><th headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2" id="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">HCM</th><th headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2" id="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ectodermal<br>findings</th><th headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2" id="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ID</th><th headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2" id="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pulmonary<br>stenosis</th><th headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2" id="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other</th></tr></thead><tbody><tr><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>BRAF</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+++&nbsp;<sup>2</sup></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically classic features</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>KRAS</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+++&nbsp;<sup>3</sup></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Craniosynostosis reported in 2 persons&nbsp;<sup>4</sup></td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>LZTR1</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">++&nbsp;<sup>5</sup></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>MAP2K1</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+++&nbsp;<sup>2</sup></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically classic features</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>MRAS</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+++</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6 of 6 reported persons&nbsp;<sup>6</sup></td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>PTPN11</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-&nbsp;<sup>7</sup></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+++</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Persons are also more likely to have short stature, pectus anomaly, easy bruising, cryptorchidism, &amp; characteristic facial features.</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>RAF1</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+++&nbsp;<sup>8</sup></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">++&nbsp;<sup>9</sup></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>RIT1</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">++&nbsp;<sup>10</sup></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">++&nbsp;<sup>11</sup></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-&nbsp;<sup>12</sup></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Persons are less likely to have short stature &amp; pectus anomalies &amp; more likely to have perinatal abnormalities, high birth weight, &amp; relative macrocephaly.</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>SOS1</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">++</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Persons are more likely to have normal stature &amp; cardiac septal defects.</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>SOS2</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">++</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_1_2 hd_h_noonan.T.noonan_syndrome_phenotype_corre_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Infrequent short stature; lymphatic abnormalities in &gt;50%&nbsp;<sup>13</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">+, ++, +++ = degree of likelihood that a given feature is present (i.e., more +s = more likely); - = a feature that is less likely to be present. Blank cells indicate that there is no known correlation between the likelihood of having a particular feature when a person has a pathogenic variant in that gene.</p></div></dd><dt></dt><dd><div><p class="no_margin">HCM = hypertrophic cardiomyopathy; ID = intellectual disability</p></div></dd><dt>1. </dt><dd><div id="noonan.TF.3.1"><p class="no_margin">Genes are listed in alphabetic order.</p></div></dd><dt>2. </dt><dd><div id="noonan.TF.3.2"><p class="no_margin"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.nava.2007.763" role="button" aria-expanded="false" aria-haspopup="true">Nava et al [2007]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.nystr_m.2008.500" role="button" aria-expanded="false" aria-haspopup="true">Nyström et al [2008]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.sarkozy.2009.695" role="button" aria-expanded="false" aria-haspopup="true">Sarkozy et al [2009]</a></p></div></dd><dt>3. </dt><dd><div id="noonan.TF.3.3"><p class="no_margin">Those with pathogenic variants in KRAS tend to have a greater likelihood and severity of intellectual disability [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.zenker.2007.131" role="button" aria-expanded="false" aria-haspopup="true">Zenker et al 2007</a>].</p></div></dd><dt>4. </dt><dd><div id="noonan.TF.3.4"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.kratz.2009.1036" role="button" aria-expanded="false" aria-haspopup="true">Kratz et al [2009]</a>
</p></div></dd><dt>5. </dt><dd><div id="noonan.TF.3.5"><p class="no_margin">In one study, 5/26 persons with a heterozygous pathogenic variant in <i>LZTR1</i> and19/26 with biallelic pathogenic variants in <i>LZTR1</i> had hypertrophic cardiomyopathy.</p></div></dd><dt>6. </dt><dd><div id="noonan.TF.3.6"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.pires.2021.3099" role="button" aria-expanded="false" aria-haspopup="true">Pires et al [2021]</a>
</p></div></dd><dt>7. </dt><dd><div id="noonan.TF.3.7"><p class="no_margin">Those with a pathogenic variant in <i>PTPN11</i> are less likely to have hypertrophic cardiomyopathy compared to those with Noonan <span class="term-highlight">syndrome</span> of other genetic causes.</p></div></dd><dt>8. </dt><dd><div id="noonan.TF.3.8"><p class="no_margin">The chance of having hypertrophic cardiomyopathy in persons with Noonan <span class="term-highlight">syndrome</span> caused by a heterozygous pathogenic variant in <i>RAF1</i> is ~85% compared to 18% for those with Noonan <span class="term-highlight">syndrome</span> in general [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.gelb.2015.13" role="button" aria-expanded="false" aria-haspopup="true">Gelb et al 2015</a>].</p></div></dd><dt>9. </dt><dd><div id="noonan.TF.3.9"><p class="no_margin">Multiple nevi, lentigines, and/or café au lait spots were reported in one third of those with <i>RAF1</i>-associated NS.</p></div></dd><dt>10. </dt><dd><div id="noonan.TF.3.10"><p class="no_margin">Hypertrophic cardiomyopathy is present in 70%-75% of persons with <i>RIT1</i>-associated NS [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.aoki.2013.173" role="button" aria-expanded="false" aria-haspopup="true">Aoki et al 2013</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.yaoita.2016.209" role="button" aria-expanded="false" aria-haspopup="true">Yaoita et al 2016</a>].</p></div></dd><dt>11. </dt><dd><div id="noonan.TF.3.11"><p class="no_margin">Including curly hair, hyperpigmentation, and wrinkled palms and soles</p></div></dd><dt>12. </dt><dd><div id="noonan.TF.3.12"><p class="no_margin">Those with <i>RIT1</i>-NS are less likely to have intellectual disability [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.bertola.2014.2952" role="button" aria-expanded="false" aria-haspopup="true">Bertola et al 2014</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.yaoita.2016.209" role="button" aria-expanded="false" aria-haspopup="true">Yaoita et al 2016</a>].</p></div></dd><dt>13. </dt><dd><div id="noonan.TF.3.13"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.lissewski.2021.51" role="button" aria-expanded="false" aria-haspopup="true">Lissewski et al [2021]</a>
</p></div></dd></dl></div></div></div></div><div id="noonan.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No genotype-phenotype correlations for <i>BRAF</i>, <i>KRAS</i>, <i>LZTR1</i>, <i>MAP2K1</i>, <i>MRAS</i>, <i>NRAS</i>, <i>RAF1</i>, <i>RASA2</i>, <i>RIT1</i>, <i>RRAS2</i>, <i>SOS1</i>, or <i>SOS2</i> have been identified.</p><p>
<b>
<i>PTPN11</i>
</b>
</p><ul><li class="half_rhythm"><div>Germline pathogenic variants at codons 61, 71, 72, and 76 are significantly associated with leukemogenesis and identify a subgroup of individuals with NS at risk for JMML [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.niihori.2005.192" role="button" aria-expanded="false" aria-haspopup="true">Niihori et al 2005</a>].</div></li><li class="half_rhythm"><div>Individuals with the <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.noonan_syndrome_notable_pathoge/?report=objectonly" target="object" rid-ob="figobnoonanTnoonansyndromenotablepathoge">p.Asn308Asp</a> pathogenic variant are said to be more likely to receive a typical education [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.jongmans.2004.56" role="button" aria-expanded="false" aria-haspopup="true">Jongmans et al 2004</a>].</div></li><li class="half_rhythm"><div>An in-frame three-nucleotide <i>PTPN11</i> deletion (<a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.noonan_syndrome_notable_pathoge/?report=objectonly" target="object" rid-ob="figobnoonanTnoonansyndromenotablepathoge">p.Gly60del</a>) in a female infant with severe features of Noonan <span class="term-highlight">syndrome</span>, including hydrops fetalis and juvenile myelomonocytic leukemia [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.yoshida.2004.63" role="button" aria-expanded="false" aria-haspopup="true">Yoshida et al 2004</a>], has been reported. The <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.noonan_syndrome_notable_pathoge/?report=objectonly" target="object" rid-ob="figobnoonanTnoonansyndromenotablepathoge">p.Asp61del</a> three-nucleotide <i>PTPN11</i> deletion has also been reported in a child with typical rather than severe NS [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.lee.2005b.7" role="button" aria-expanded="false" aria-haspopup="true">Lee et al 2005b</a>].</div></li></ul></div><div id="noonan.Nomenclature"><h3>Nomenclature</h3><p>An early term for NS, "male Turner <span class="term-highlight">syndrome</span>," incorrectly implied that the condition would not be found in females.</p><p>In 1949, Otto Ullrich reported affected individuals and noted a similarity between their features and those in a strain of mice bred by Bonnevie (webbed neck and lymphedema). The term "Bonnevie-Ullrich <span class="term-highlight">syndrome</span>" became popular, particularly in Europe.</p></div><div id="noonan.Prevalence"><h3>Prevalence</h3><p>NS is common and reported to occur in between 1:1,000 and 1:2,500 persons. Mild expression is likely to be overlooked.</p></div></div><div id="noonan.Genetically_Related_Allelic_Disor"><h2 id="_noonan_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p>The autosomal dominant allelic disorders summarized in <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.allelic_disorders_to_consider_i/?report=objectonly" target="object" rid-ob="figobnoonanTallelicdisorderstoconsideri">Table 4</a> have clinical features overlapping those associated with Noonan <span class="term-highlight">syndrome</span> and should be considered in the differential diagnosis.</p><div id="noonan.T.allelic_disorders_to_consider_i" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Allelic Disorders to Consider in the Differential Diagnosis of Noonan <span class="term-highlight">Syndrome</span></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.allelic_disorders_to_consider_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.T.allelic_disorders_to_consider_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_noonan.T.allelic_disorders_to_consider_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Genes</th><th id="hd_h_noonan.T.allelic_disorders_to_consider_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_noonan.T.allelic_disorders_to_consider_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_noonan.T.allelic_disorders_to_consider_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BRAF</i><br><i>KRAS</i><br><i>MAP2K1</i><br><i>MAP2K2</i>&nbsp;<sup>2</sup></td><td headers="hd_h_noonan.T.allelic_disorders_to_consider_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<a href="https://www.ncbi.nlm.nih.gov/books/n/gene/cfc/">CFC <span class="term-highlight">syndrome</span></a>
</td><td headers="hd_h_noonan.T.allelic_disorders_to_consider_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CFC <span class="term-highlight">syndrome</span> &amp; NS have the greatest overlap in features. CFC <span class="term-highlight">syndrome</span> has similar cardiac &amp; lymphatic findings&nbsp;<sup>1</sup> but more severe ID, w/higher likelihood of structural CNS anomalies; skin pathology is more florid; GI problems are more severe &amp; long lasting; bleeding diathesis is rare. Facial appearance tends to be coarser, dolichocephaly &amp; absent eyebrows are more frequent, blue eyes less common.</td></tr><tr><td headers="hd_h_noonan.T.allelic_disorders_to_consider_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>BRAF</i>
<br>
<i>MAP2K1</i>
<br>
<i>PTPN11</i>
<br>
<i>RAF1</i>
</td><td headers="hd_h_noonan.T.allelic_disorders_to_consider_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<a href="https://www.ncbi.nlm.nih.gov/books/n/gene/leopard/">Noonan <span class="term-highlight">syndrome</span> w/multiple lentigines</a>
</td><td headers="hd_h_noonan.T.allelic_disorders_to_consider_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Formerly referred to as LEOPARD <span class="term-highlight">syndrome</span>. NSML is assoc w/variable expression &amp; shows significant overlap w/NS. In early childhood the NSML phenotype can be typical of NS; w/age, other characteristic features (incl lentigines &amp; hearing loss) develop.</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = autosomal dominant; CFC = cardiofaciocutaneous; GI = gastrointestinal; ID = intellectual disability; LEOPARD = <i>l</i>entigines, <i>E</i>KG abnormalities, <i>o</i>cular hypertelorism, <i>p</i>ulmonary stenosis, <i>a</i>bnormalities of genitalia, <i>r</i>etardation of growth, <i>d</i>eafness; MOI = mode of inheritance; NS = Noonan <span class="term-highlight">syndrome</span>; NMSL = Noonan <span class="term-highlight">syndrome</span> with multiple lentigines</p></div></dd><dt>1. </dt><dd><div id="noonan.TF.4.1"><p class="no_margin"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.noonan.2001" role="button" aria-expanded="false" aria-haspopup="true">Noonan [2001]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.armour.2008.249" role="button" aria-expanded="false" aria-haspopup="true">Armour &amp; Allanson [2008]</a></p></div></dd><dt>2. </dt><dd><div id="noonan.TF.4.2"><p class="no_margin">Pathogenic variants in <i>BRAF</i> account for ~75% of CFC <span class="term-highlight">syndrome</span>; <i>MAP2K1</i> and <i>MAP2K2</i> account for ~25%; <i>KRAS</i> &lt;2%.</p></div></dd></dl></div></div></div><p>
<b>Other allelic disorders</b>
</p><ul><li class="half_rhythm"><div>Heterozygous germline pathogenic variants in <i>LZTR1</i> are also known to be associated with <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/schwann/">schwannomatosis</a> type 2.</div></li><li class="half_rhythm"><div>Heterozygous germline pathogenic variants in <i>SOS1</i> are also known to be associated with hereditary gingival fibromatosis (OMIM <a href="https://omim.org/entry/135300" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">135300</a>).</div></li><li class="half_rhythm"><div><i>PTPN11</i> intragenic deletion and splice site variants are associated with autosomal dominant metachondromatosis [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.mcfarlane.2016.102" role="button" aria-expanded="false" aria-haspopup="true">McFarlane et al 2016</a>].</div></li></ul><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with germline pathogenic variants in <i>MRAS</i>, <i>NRAS</i>, <i>RASA2</i>, <i>RIT1</i>, <i>RRAS2</i>, or <i>SOS2</i>.</p><p>Mosaic activating pathogenic variants in <i>KRAS</i> are associated with <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/eccl/">encephalocraniocutaneous lipomatosis</a> (ECCL). The pathogenic variants reported in ECCL are of postzygotic origin but arise early during development. ECCL comprises a spectrum of predominantly congenital anomalies. In its typical form, ECCL is characterized by congenital skin, eye, and brain anomalies, in particular intracranial and spinal lipomas.</p><p><b>Sporadic tumors</b> (including leukemia and solid tumors) occurring as single tumors in the absence of any other findings of Noonan <span class="term-highlight">syndrome</span> may contain a somatic pathogenic nucleotide variant in <i>BRAF</i>, <i>KRAS</i>, <i>LZTR1</i>, <i>MAP2K1</i>, <i>MRAS</i>, <i>NRAS</i>, <i>PTPN11</i>, <i>RAF1</i>, or <i>RRAS2</i> that is <b>not</b> present in the germline. In these circumstances predisposition to these tumors is not heritable. See Molecular Genetics, <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Cancer_and_Benign_Tumors">Cancer and Benign Tumors</a>.</p></div><div id="noonan.Differential_Diagnosis"><h2 id="_noonan_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Turner <span class="term-highlight">syndrome</span>,</b> typically seen in females, is differentiated from Noonan <span class="term-highlight">syndrome</span> (NS) by demonstration of a sex chromosome abnormality on cytogenetic studies in affected individuals. The phenotype of Turner <span class="term-highlight">syndrome</span> is quite different from that of NS, when one considers face, heart, development, and kidneys. In Turner <span class="term-highlight">syndrome</span>, renal anomalies are more common, developmental delay is much less frequently found, and left-sided heart defects are the rule.</p><p>Genes of interest in the differential diagnosis of NS are summarized in <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.genes_of_interest_in_the_differ/?report=objectonly" target="object" rid-ob="figobnoonanTgenesofinterestinthediffer">Table 5</a>.</p><div id="noonan.T.genes_of_interest_in_the_differ" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Genes of Interest in the Differential Diagnosis of Noonan <span class="term-highlight">Syndrome</span></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.genes_of_interest_in_the_differ/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.T.genes_of_interest_in_the_differ_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical Characteristics / Comment</th></tr></thead><tbody><tr><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BRAF</i><br><i>KRAS</i><br><i>MAP2K1</i><br><i>MAP2K2</i>&nbsp;<sup>1</sup></td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<a href="https://www.ncbi.nlm.nih.gov/books/n/gene/cfc/">Cardiofaciocutaneous <span class="term-highlight">syndrome</span></a>
</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Genetically_Related_Allelic_Disor">Genetically Related Disorders</a>.</td></tr><tr><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>BRAF</i>
<br>
<i>MAP2K1</i>
<br>
<i>PTPN11</i>
<br>
<i>RAF1</i>
</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/books/n/gene/leopard/">Noonan <span class="term-highlight">syndrome</span> w/multiple lentigines</a> (previously referred to as LEOPARD <span class="term-highlight">syndrome</span>)</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Genetically_Related_Allelic_Disor">Genetically Related Disorders</a>.</td></tr><tr><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CBL</i>&nbsp;<sup>2</sup></td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Noonan <span class="term-highlight">syndrome</span>-like disorder ± juvenile myelomonocytic leukemia (OMIM <a href="https://omim.org/entry/613563" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613563</a>)</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variable phenotype characterized by relatively high frequency of neurologic features, predisposition to JMML, low prevalence of cardiac defects, ↓ growth, &amp; cryptorchidism&nbsp;<sup>3</sup></td></tr><tr><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>FGD1</i>
</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">X-linked Aarskog <span class="term-highlight">syndrome</span> (OMIM <a href="https://omim.org/entry/305400" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">305400</a>)</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Characterized by DD, short stature, congenital heart defects, &amp; distinctive facies</td></tr><tr><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>HRAS</i>
</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<a href="https://www.ncbi.nlm.nih.gov/books/n/gene/costello/"><span class="term-highlight">Costello</span> <span class="term-highlight">syndrome</span></a>
</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically characterized by failure to thrive in infancy due to severe postnatal feeding difficulties; short stature; DD or ID; coarse facial features; curly or sparse, fine hair; loose, soft skin w/deep palmar &amp; plantar creases; papillomata of the face &amp; perianal region; diffuse hypotonia &amp; joint laxity w/ulnar deviation of wrists &amp; fingers; tight Achilles tendons; &amp; cardiac involvement. Relative or absolute macrocephaly is typical.</td></tr><tr><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>NF1</i>
</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/books/n/gene/nf1/">Neurofibromatosis 1</a> (NF1)</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NF1 shares some features w/NS, incl short stature, learning difficulties, &amp; café au lait patches. Rare affected persons may have a NS-like facial appearance.&nbsp;<sup>4</sup><br>Watson <span class="term-highlight">syndrome</span>, an NF1 variant, is characterized by multiple café au lait spots, pulmonic stenosis, ID, &amp; short stature.</td></tr><tr><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PPP1CB</i><br><i>SHOC2</i>&nbsp;<sup>2</sup></td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Noonan <span class="term-highlight">syndrome</span> w/loose anagen hair (OMIM <a href="https://omim.org/phenotypicSeries/PS607721" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS607721</a>)</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NS-like features or, in a small proportion of affected persons, the classic NS phenotype.&nbsp;<sup>5</sup> The recurrent pathogenic missense <i>SHOC2</i> variant 4A&gt;G has been found in a subgroup w/features of NS but also GH deficiency; distinctive hyperactive behavior that improves w/age in most; hair anomalies; darkly pigmented skin w/eczema or ichthyosis; hypernasal voice; &amp; overrepresentation of mitral valve dysplasia &amp; septal defects in comparison w/classic NS&nbsp;<sup>1,&nbsp;6</sup></td></tr><tr><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>SPRED1</i>
</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<a href="https://www.ncbi.nlm.nih.gov/books/n/gene/legius/">Legius <span class="term-highlight">syndrome</span></a>
</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_noonan.T.genes_of_interest_in_the_differ_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Majority: café au lait macules, 30%-50% skin freckling, 30% developmental issues, 15% Noonan-like facial features</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = autosomal dominant; DD = developmental delay; GH = growth hormone; GI = gastrointestinal; ID = intellectual disability; JMML = juvenile myelomonocytic leukemia; MOI = mode of inheritance; NS = Noonan <span class="term-highlight">syndrome</span>; XL = X-linked</p></div></dd><dt>1. </dt><dd><div id="noonan.TF.5.1"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.cordeddu.2009.1022" role="button" aria-expanded="false" aria-haspopup="true">Cordeddu et al [2009]</a>
</p></div></dd><dt>2. </dt><dd><div id="noonan.TF.5.2"><p class="no_margin">Due to the significant phenotypic overlap with classic NS, most RASopathy diagnostic gene panels include testing for the common <i>SHOC2</i> variant and <i>CBL</i> gene sequencing.</p></div></dd><dt>3. </dt><dd><div id="noonan.TF.5.3"><p class="no_margin"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.martinelli.2010.250" role="button" aria-expanded="false" aria-haspopup="true">Martinelli et al [2010]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.niemeyer.2010.794" role="button" aria-expanded="false" aria-haspopup="true">Niemeyer et al [2010]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.martinelli.2015.787" role="button" aria-expanded="false" aria-haspopup="true">Martinelli et al [2015]</a></p></div></dd><dt>4. </dt><dd><div id="noonan.TF.5.4"><p class="no_margin">This could be caused by chance concurrence of NS and NF1 [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.colley.1996.59" role="button" aria-expanded="false" aria-haspopup="true">Colley et al 1996</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.bertola.2005.242" role="button" aria-expanded="false" aria-haspopup="true">Bertola et al 2005</a>]. However, most often it appears to be a NS-like facial appearance in a person with a pathogenic variant in <i>NF1</i>, sometimes in the presence of a variant NF1 phenotype [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.stevenson.2006.246" role="button" aria-expanded="false" aria-haspopup="true">Stevenson et al 2006</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.nystr_m.2009.524" role="button" aria-expanded="false" aria-haspopup="true">Nyström et al 2009</a>].</p></div></dd><dt>5. </dt><dd><div id="noonan.TF.5.5"><p class="no_margin">B Kerr, personal observation</p></div></dd><dt>6. </dt><dd><div id="noonan.TF.5.6"><p class="no_margin"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.gripp.2016.2237" role="button" aria-expanded="false" aria-haspopup="true">Gripp et al [2016]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.huckstadt.2021.1256" role="button" aria-expanded="false" aria-haspopup="true">Huckstadt et al [2021]</a></p></div></dd></dl></div></div></div><p><b>Other.</b> NS should be distinguished from other syndromes/conditions with developmental delay, short stature, congenital heart defects, and distinctive facies, especially the following:</p><ul><li class="half_rhythm"><div>Autosomal dominant Aarskog <span class="term-highlight">syndrome</span> of unknown genetic cause (OMIM <a href="https://omim.org/entry/100050" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">100050</a>)</div></li><li class="half_rhythm"><div>In utero exposure to alcohol or primidone</div></li></ul></div><div id="noonan.Management"><h2 id="_noonan_Management_">Management</h2><p>Management guidelines have been developed by DYSCERNE, a European consortium [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF86" role="button" aria-expanded="false" aria-haspopup="true">Noonan <span class="term-highlight">Syndrome</span> Guideline Development Group 2010</a>] (<a href="https://rasopathiesnet.org/wp-content/uploads/2014/01/265_Noonan_Guidelines.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>); a separate set has been published by an American consortium working with the Noonan <span class="term-highlight">Syndrome</span> Support Group [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.romano.2010.746" role="button" aria-expanded="false" aria-haspopup="true">Romano et al 2010</a>] and in the <i>Lancet</i> [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.roberts.2013.333" role="button" aria-expanded="false" aria-haspopup="true">Roberts et al 2013</a>].</p><div id="noonan.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with Noonan <span class="term-highlight">syndrome</span>, the evaluations summarized in <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.recommended_evaluations_followi/?report=objectonly" target="object" rid-ob="figobnoonanTrecommendedevaluationsfollowi">Table 6</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended.</p><div id="noonan.T.recommended_evaluations_followi" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with Noonan <span class="term-highlight">Syndrome</span></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.recommended_evaluations_followi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.T.recommended_evaluations_followi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Constitutional</b>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Measurements of growth parameters</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>On NS-specific growth charts</div></li><li class="half_rhythm"><div>To identify those w/failure to thrive &amp;/or short stature</div></li></ul>
</td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Endocrine</b>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bone age, growth hormone &amp; thyroid function studies&nbsp;<sup>1</sup></td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In children w/short stature (height &gt;2 SD below standard growth curve or crossing 2 major height %iles)</td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Gastrointestinal/</b>
<br>
<b>Feeding</b>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gastroenterology / nutrition / feeding team eval</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>In infants w/poor weight gain, dysphagia</div></li><li class="half_rhythm"><div>Eval for malrotation if persistent unexplained vomiting</div></li></ul>
</td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Development</b>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Developmental assessment</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To incl:
<ul><li class="half_rhythm"><div>Motor, adaptive, cognitive, &amp; speech-language eval</div></li><li class="half_rhythm"><div>Eval for early intervention&nbsp;/ special education</div></li></ul>
</td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Psychiatric/</b>
<br>
<b>Behavioral</b>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neuropsychiatric eval may be considered.</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For those age &gt;12 mos: screen for behavior concerns, autism, depression, ADHD, &amp; anxiety (some symptoms may not be present until adulthood).</td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Cardiovascular</b>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Echocardiogram &amp; EKG</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To identify congenital heart defects, cardiomyopathy, &amp;/or cardiac conduction abnormalities</td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Genitourinary</b>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Kidney ultrasound</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To assess for renal anomalies; if present, referral to urologist</td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Assessment for cryptorchidism in males</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to urologist if cryptorchidism is present</td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Musculoskeletal</b>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PT/OT eval</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To incl:
<ul><li class="half_rhythm"><div>Assessment of gross motor &amp; fine motor skills</div></li><li class="half_rhythm"><div>Need for PT (to improve gross motor skills) &amp;/or OT (to improve fine motor skills)</div></li></ul>
</td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Consider radiographs of the spine if asymmetry or scoliosis is present on physical exam.</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider referral to orthopedist.</td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Hematologic/</b>
<br>
<b>Lymphatic</b>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In consultation w/hematologist: bleeding history, CBC w/differential, PT/aPTT, factor XI, XII, IX, VIII, vWf, &amp; platelet aggregation testing</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">If initial screening was performed before age 12 mos, repeat after age 12 mos.&nbsp;<sup>2</sup></td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Eyes</b>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ophthalmologic eval</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To assess for amblyopia, refractive error, nystagmus, strabismus, &amp; clinically significant ptosis</td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Hearing</b>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Audiologic eval</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess for hearing loss &amp; middle ear effusion.</td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Integument</b>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Full skin exam</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider referral to dermatologist in those w/multiple lentigines requiring monitoring or significant xeroderma.&nbsp;<sup>3</sup></td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Neurologic</b>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neurologic eval</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To incl brain &amp; spine MRI if signs or symptoms consistent w/possible Chiari malformation</td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Genetic</b>
<br>
<b>counseling</b>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">By genetics professionals&nbsp;<sup>4</sup></td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To inform affected persons &amp; their families re nature, MOI, &amp; implications of NS in order to facilitate medical &amp; personal decision making</td></tr><tr><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Family support</b>
<br>
<b>&amp; resources</b>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess need for:
<ul><li class="half_rhythm"><div>Community or <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Resources">online resources</a> such as <a href="https://p2pusa.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Parent to Parent</a>;</div></li><li class="half_rhythm"><div>Social work involvement for parental support;</div></li><li class="half_rhythm"><div>Home nursing referral.</div></li></ul>
</td><td headers="hd_h_noonan.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">ADHD = attention-deficit/hyperactivity disorder; MOI = mode of inheritance; NS = Noonan <span class="term-highlight">syndrome</span>; OT = occupational therapy; PT = physical therapy; PT/aPTT = prothrombin/activated partial thromboplastin time; vWF = von Willebrand factor</p></div></dd><dt>1. </dt><dd><div id="noonan.TF.6.1"><p class="no_margin">Thyroid function tests may include TSH and free T4.</p></div></dd><dt>2. </dt><dd><div id="noonan.TF.6.2"><p class="no_margin"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.romano.2010.746" role="button" aria-expanded="false" aria-haspopup="true">Romano et al [2010]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.roberts.2013.333" role="button" aria-expanded="false" aria-haspopup="true">Roberts et al [2013]</a></p></div></dd><dt>3. </dt><dd><div id="noonan.TF.6.3"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.quaio.2013.1079" role="button" aria-expanded="false" aria-haspopup="true">Quaio et al [2013]</a>
</p></div></dd><dt>4. </dt><dd><div id="noonan.TF.6.4"><p class="no_margin">Medical geneticist, certified genetic counselor, certified advanced genetic nurse</p></div></dd></dl></div></div></div></div><div id="noonan.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="noonan.T.treatment_of_manifestations_in" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with Noonan <span class="term-highlight">Syndrome</span></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.treatment_of_manifestations_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.T.treatment_of_manifestations_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/<br>Concern</th><th id="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Short stature</b>
</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">GH therapy may be considered.</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>No standard dose has been established.</div></li><li class="half_rhythm"><div>No apparent correlation between dosage used &amp; final height, though earlier age at initiation of GH therapy is assoc w/↑ final adult height.</div></li><li class="half_rhythm"><div>Short stature due to NS is an FDA-approved indication for GH treatment.</div></li><li class="half_rhythm"><div>No evidence supports ↑ prevalence of neoplasm, cardiac, or other comorbidities in those treated w/GH.&nbsp;<sup>1</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Feeding</b>
<br>
<b>difficulties</b>
</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consideration of nasogastric tube feedings in infants w/poor growth, esp if they have a congenital heart defect or cardiomyopathy</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Invasive intervention (i.e., placement of gastrostomy tube) may be needed, though feeding issues are often self-limited.</td></tr><tr><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>DD/ID</b>
</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Developmental_Delay__Intellectual">Developmental Delay / Intellectual Disability Management Issues</a>.</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Psychiatric/</b>
<br>
<b>Behavioral</b>
</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment for ADHD &amp; any neuropsychiatric features &amp;/or behavioral problems</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to a neurodevelopmental specialist or psychiatrist, depending on age, may be considered.</td></tr><tr><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Congenital heart defects</b>
</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment per cardiologist</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pulmonary valve stenosis treated w/percutaneous balloon pulmonary valvuloplasty has a higher reintervention rate vs pulmonary valve stenosis w/o NS but is still considered 1st-line treatment.&nbsp;<sup>2</sup></td></tr><tr><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>HCM</b>
</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment per cardiologist</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HCM is assoc w/substantial early mortality; infants presenting before age 6 mos in congestive heart failure have worst prognosis (2-yr survival of 30%).&nbsp;<sup>3</sup></td></tr><tr><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Cryptorchidism</b>
</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment per urologist</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Renal anomalies&nbsp;/</b>
<br>
<b>Hydronephrosis</b>
</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment per urologist &amp;/or nephrologist</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Bleeding</b>
<br>
<b>diathesis</b>
</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment per hematologist</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Specific treatment for serious bleeding may be guided by knowledge of a factor deficiency or platelet aggregation anomaly.</div></li><li class="half_rhythm"><div>Factor VIIa has also been used in an infant w/NS who had normal platelet count &amp; prothrombin &amp; partial thromboplastin times to control severe postoperative blood loss due to gastritis.&nbsp;<sup>4</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Abnormal</b>
<br>
<b>vision &amp;/or</b>
<br>
<b>strabismus</b>
</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment(s) as recommended by ophthalmologist</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Community vision services through early intervention or school district</td></tr><tr><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Hearing</b>
</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hearing aids may be helpful; as per otolaryngologist.</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Community hearing services through early intervention or school district</td></tr><tr><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Chiari</b>
<br>
<b>malformation</b>
</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment per neurosurgeon</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Juvenile</b>
<br>
<b>myelomonocytic</b>
<br>
<b>leukemia &amp; other</b>
<br>
<b>malignancies</b>
</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment per oncologist</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Family/</b>
<br>
<b>Community</b>
</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Ensure appropriate social work involvement to connect families w/local resources, respite, &amp; support.</div></li><li class="half_rhythm"><div>Coordinate care to manage multiple subspecialty appointments, equipment, medications, &amp; supplies.</div></li></ul>
</td><td headers="hd_h_noonan.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Ongoing assessment of need for palliative care involvement &amp;/or home nursing</div></li><li class="half_rhythm"><div>Consider involvement in adaptive sports or <a href="https://www.specialolympics.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Special Olympics</a>.</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">ADHD = attention-deficit/hyperactivity disorder; DD/ID = developmental delay&nbsp;/ intellectual disability; GH = growth hormone; HCM = hypertrophic cardiomyopathy; NS = Noonan <span class="term-highlight">syndrome</span></p></div></dd><dt>1. </dt><dd><div id="noonan.TF.7.1"><p class="no_margin"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.romano.2010.746" role="button" aria-expanded="false" aria-haspopup="true">Romano et al [2010]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.rohrer.2020.380" role="button" aria-expanded="false" aria-haspopup="true">Rohrer et al [2020]</a></p></div></dd><dt>2. </dt><dd><div id="noonan.TF.7.2"><p class="no_margin"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.prendiville.2014.629" role="button" aria-expanded="false" aria-haspopup="true">Prendiville et al [2014]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.linglart.2020.73" role="button" aria-expanded="false" aria-haspopup="true">Linglart &amp; Gelb [2020]</a></p></div></dd><dt>3. </dt><dd><div id="noonan.TF.7.3"><p class="no_margin"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.hickey.2011.41" role="button" aria-expanded="false" aria-haspopup="true">Hickey et al [2011]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.wilkinson.2012.442" role="button" aria-expanded="false" aria-haspopup="true">Wilkinson et al [2012]</a></p></div></dd><dt>4. </dt><dd><div id="noonan.TF.7.4"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.tofil.2005.352" role="button" aria-expanded="false" aria-haspopup="true">Tofil et al [2005]</a>
</p></div></dd></dl></div></div></div><div id="noonan.Developmental_Delay__Intellectual"><h4>Developmental Delay / Intellectual Disability Management Issues</h4><p>The following information represents typical management recommendations for individuals with developmental delay&nbsp;/ intellectual disability in the United States; standard recommendations may vary from country to country.</p><p><b>Ages 0-3 years.</b> Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy as well as infant mental health services, special educators, and sensory impairment specialists. In the US, early intervention is a federally funded program available in all states that provides in-home services to target individual therapy needs.</p><p><b>Ages 3-5 years.</b> In the US, developmental preschool through the local public school district is available for those who qualify. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed for those who qualify based on established motor, language, social, or cognitive delay. The early intervention program typically assists with this transition. Developmental preschool is center based.</p><p><b>All ages.</b> Consultation with a developmental pediatrician may be considered to ensure the involvement of appropriate community, state, and educational agencies (US) and to support parents in maximizing quality of life. Some issues to consider:</p><ul><li class="half_rhythm"><div>IEP services:</div><ul><li class="half_rhythm"><div>An IEP provides specially designed instruction and related services to children who qualify.</div></li><li class="half_rhythm"><div>IEP services will be reviewed annually to determine whether any changes are needed.</div></li><li class="half_rhythm"><div>Special education law requires that children participating in an IEP be in the least restrictive environment feasible at school and included in general education as much as possible, when and where appropriate.</div></li><li class="half_rhythm"><div>Vision and hearing consultants should be a part of the child's IEP team to support access to academic material.</div></li><li class="half_rhythm"><div>PT, OT, and speech services will be provided in the IEP to the extent that the need affects the child's access to academic material. Beyond that, private supportive therapies based on the affected individual's needs may be considered. Specific recommendations regarding type of therapy can be made by a developmental pediatrician, as needed.</div></li><li class="half_rhythm"><div>As a child enters the teen years, a transition plan should be discussed and incorporated in the IEP. For those receiving IEP services, the public school district is required to provide services until age 21.</div></li></ul></li><li class="half_rhythm"><div>A 504 plan (Section 504: a US federal statute that prohibits discrimination based on disability) can be considered for those who require accommodations or modifications such as front-of-class seating, assistive technology devices, classroom scribes, extra time between classes, modified assignments, and enlarged text.</div></li><li class="half_rhythm"><div>Developmental Disabilities Administration (DDA) enrollment may be considered. DDA is a US public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.</div></li><li class="half_rhythm"><div>Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.</div></li></ul></div></div><div id="noonan.Surveillance"><h3>Surveillance</h3><div id="noonan.T.recommended_surveillance_for_in" class="table"><h3><span class="label">Table 8. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with Noonan <span class="term-highlight">Syndrome</span></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.recommended_surveillance_for_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.T.recommended_surveillance_for_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Constitutional</b>
</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Measurement of growth parameters on NS-specific growth charts</div></li><li class="half_rhythm"><div>Eval of nutritional status in infants &amp; toddlers</div></li></ul>
</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_3" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;">At each visit</td></tr><tr><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Development</b>
</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor developmental progress &amp; educational needs.</td></tr><tr><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Neurologic</b>
</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess for new manifestations, e.g., chronic headache, neck pain, changes in tone, dizziness, or signs/symptoms of OSA that may indicate a Chiari malformation.&nbsp;<sup>1</sup></td></tr><tr><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Integument</b>
</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Skin exam</td></tr><tr><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Family/</b>
<br>
<b>Community</b>
</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources) &amp; care coordination.</td></tr><tr><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Psychiatric/</b>
<br>
<b>Behavioral</b>
</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Behavioral assessment for anxiety, attention, &amp; depression</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At each visit starting in early childhood, as age appropriate</td></tr><tr><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Cardiovascular</b>
</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In children &lt;5 yrs: if initial cardiac eval is normal</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At least annual cardiac eval until age 5 yrs or as clinically indicated</td></tr><tr><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">In children &gt;5 yrs through adulthood</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At least every 5 yrs or as clinically indicated</td></tr><tr><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Eyes</b>
</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ophthalmology eval</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annually in childhood &amp; adolescence or as clinically indicated</td></tr><tr><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Hearing</b>
</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Audiology eval</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annually in early childhood or as clinically indicated</td></tr><tr><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Malignancy/</b>
<br>
<b>JMML&nbsp;<sup>2</sup></b>
</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For those w/pathogenic <i>PTPN11</i> or <i>KRAS</i> variants&nbsp;<sup>3</sup>: consider physical exam w/assessment of spleen size &amp; CBC.</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 3-6 mos until age 5 yrs</td></tr><tr><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<b>Coagulation/</b>
<br>
<b>Bleeding</b>
</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In consultation w/hematologist: bleeding history, CBC w/differential, PT/aPTT, factor XI, XII, IX, VIII, vWf, &amp; platelet aggregation testing</td><td headers="hd_h_noonan.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Prior to any surgical procedure or if there is a bleeding history</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">CBC = complete blood count; PT/aPTT = prothrombin/activated partial thromboplastin time; vWF = von Willebrand factor; JMML = juvenile myelomonocytic leukemia; OSA = obstructive sleep apnea</p></div></dd><dt>1. </dt><dd><div id="noonan.TF.8.1"><p class="no_margin">With referral to neurologist and consideration of head MRI to include sections through the base of the skull to assess for Chiari malformation</p></div></dd><dt>2. </dt><dd><div id="noonan.TF.8.2"><p class="no_margin">Despite the apparent increased incidence of hematologic and solid tumor malignancies, no consensus surveillance strategies have been evaluated or recommended.</p></div></dd><dt>3. </dt><dd><div id="noonan.TF.8.3"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.villani.2017.e83" role="button" aria-expanded="false" aria-haspopup="true">Villani et al [2017]</a>
</p></div></dd></dl></div></div></div></div><div id="noonan.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Aspirin therapy should be avoided because it may exacerbate a bleeding diathesis.</p></div><div id="noonan.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for genetic counseling purposes.</p></div><div id="noonan.Pregnancy_Management"><h3>Pregnancy Management</h3><p>For affected women who are pregnant, consider referral to an adult congenital heart program for peripartum evaluation and management.</p><p>Pregnancy is generally a time of increased coagulation, but consider a hematology referral if the pregnant woman has a history of bleeding abnormalities and/or has not undergone previous screening for coagulopathy.</p></div><div id="noonan.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>The MEK inhibitor trametinib was given under compassionate use to two infants with pathogenic variants in <i>RIT1</i> and progressive, congenital hypertrophic cardiomyopathy. Trametinib is a highly selective reversible allosteric inhibitor of MEK1/2 activity. In both cases, there was reversal of progressive myocardial hypertrophy and valvar obstruction along with a catch-up pattern of somatic growth [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.andelfinger.2019.2237" role="button" aria-expanded="false" aria-haspopup="true">Andelfinger et al 2019</a>].</p><p><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.dori.2020.e20200167" role="button" aria-expanded="false" aria-haspopup="true">Dori et al [2020]</a> reported an individual age 14 years with <i>SOS1</i>-related NS who had resolution of mesenteric and retroperitoneal lymphangiectasia and chylothorax after treatment with trametinib, with complete remodeling of the lymphatic system.</p><p>Andrew Dauber, MD, Children's National Research Institute, is enrolling children with genetic causes of short stature, including Noonan <span class="term-highlight">syndrome</span>, for a vosoritide treatment trial. Vasoritide is a selective NPR-B agonist that targets the growth plate. See <a href="https://clinicaltrials.gov/ct2/show/NCT04219007" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Trials</a>.</p><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="https://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="noonan.Genetic_Counseling"><h2 id="_noonan_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members; it is not meant to address all personal, cultural, or
ethical issues that may arise or to substitute for consultation with a genetics
professional</i>. —ED.</p><div id="noonan.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Noonan <span class="term-highlight">syndrome</span> (NS) caused by pathogenic variants in <i>BRAF</i>, <i>KRAS</i>, <i>MAP2K1</i>, <i>MRAS</i>, <i>NRAS</i>, <i>PTPN11</i>, <i>RAF1</i>, <i>RASA2</i>, <i>RIT1</i>, <i>RRAS2</i>, <i>SOS1</i>, or <i>SOS2</i> is inherited in an autosomal dominant manner.</p><p>NS caused by pathogenic variants in <i>LZTR1</i> can be inherited in an autosomal dominant or autosomal recessive manner.</p></div><div id="noonan.Autosomal_Dominant_Inheritance__R"><h3>Autosomal Dominant Inheritance ‒ Risk to Family Members</h3><p>
<b>Parents of a proband</b>
</p><ul><li class="half_rhythm"><div>30%-75% of individuals diagnosed with NS have an affected parent. (Note: Because NS is associated with variable expressivity and the manifestations of the disorder are frequently subtle, many affected adults are diagnosed only after the birth of a more obviously affected infant.)</div></li><li class="half_rhythm"><div>A proband with NS may have the disorder as the result of a <i>de novo</i> pathogenic variant in an NS-related gene.</div></li><li class="half_rhythm"><div>In simplex cases (i.e., those with no known family history), paternal origin of the <i>de novo</i> pathogenic variant has been found universally to date [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.yoon.2013.917" role="button" aria-expanded="false" aria-haspopup="true">Yoon et al 2013</a>]. In this cohort, advanced paternal age was observed along with a significant sex-ratio bias favoring transmission to males, a finding that is thus far unexplained.</div></li><li class="half_rhythm"><div>If the proband is the only family member known to have NS, recommended evaluations of both parents include the following:</div><ul><li class="half_rhythm"><div>A thorough physical examination with particular attention to the features of NS; echo- and electrocardiography; coagulation screening; and examination of photographs of the face at all ages for characteristic features of NS</div></li><li class="half_rhythm"><div>Molecular genetic testing if the NS-causing pathogenic variant in the proband is known</div></li></ul></li><li class="half_rhythm"><div>If the proband has an NS-causing pathogenic variant that is not identified in either parent and parental identity testing has confirmed biological maternity and paternity, the following possibilities should be considered:</div><ul><li class="half_rhythm"><div>The proband has a <i>de novo</i> pathogenic variant.</div></li><li class="half_rhythm"><div>The proband inherited a pathogenic variant from a parent with germline (or somatic and germline) mosaicism. Note: Testing of parental leukocyte DNA may not detect all instances of somatic mosaicism and will not detect a pathogenic variant that is present in the germ cells only.</div></li></ul></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with NS may appear to be negative because of failure to recognize the disorder in affected family members. Therefore, an apparently negative family history cannot be confirmed without appropriate clinical evaluation of the parents and/or molecular genetic testing (to establish that neither parent is heterozygous for the pathogenic variant identified in the proband).</div></li></ul><p><b>Sibs of a proband.</b> The risk to the sibs of a proband depends on the clinical/genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent is affected and/or is known to have the pathogenic variant identified in the proband, the risk to the sibs is 50%. Because there can be significant intrafamilial variability, sibs may not have the same phenotypic findings as the proband.</div></li><li class="half_rhythm"><div>If the parents are clinically unaffected and the proband has an NS-causing pathogenic variant that cannot be detected in the leukocyte DNA of either parent, the recurrence risk to sibs is slightly greater than that of the general population because of the possibility of parental germline mosaicism (germline mosaicism for the <i>PTPN11</i> c.922A&gt;G pathogenic variant has been reported [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.yoon.2013.917" role="button" aria-expanded="false" aria-haspopup="true">Yoon et al 2013</a>]).</div></li></ul><p><b>Offspring of a proband.</b> Each child of an individual with NS has a 50% chance of inheriting the NS-related pathogenic variant.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the proband's parents: if a parent is affected and/or is known to have the familial pathogenic variant, the parent's family members may be at risk.</p></div><div id="noonan.Autosomal_Recessive_Inheritance"><h3>Autosomal Recessive Inheritance ‒ Risk to Family Members</h3><p>
<b>Parents of a proband</b>
</p><ul><li class="half_rhythm"><div>The parents of an affected child are presumed to be heterozygous for one <i>LZTR1</i> pathogenic variant.</div></li><li class="half_rhythm"><div>Molecular genetic testing is recommended for the parents of a proband to confirm that both parents are heterozygous for an <i>LZTR1</i> pathogenic variant and to allow reliable recurrence risk assessment. If a pathogenic variant is detected in only one parent and parental identity testing has confirmed biological maternity and paternity, the following possibilities should be considered:</div><ul><li class="half_rhythm"><div>One of the pathogenic variants identified in the proband occurred as a <i>de novo</i> event in the proband or as a postzygotic <i>de novo</i> event in a mosaic parent [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.j_nsson.2017.519" role="button" aria-expanded="false" aria-haspopup="true">Jónsson et al 2017</a>].</div></li><li class="half_rhythm"><div>Uniparental isodisomy for the parental chromosome with the pathogenic variant resulted in homozygosity for the pathogenic variant in the proband.</div></li></ul></li><li class="half_rhythm"><div>Heterozygotes may be asymptomatic [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.johnston.2018.1175" role="button" aria-expanded="false" aria-haspopup="true">Johnston et al 2018</a>] or may have mild features of NS [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.jenkins.2020.e002690" role="button" aria-expanded="false" aria-haspopup="true">Jenkins et al 2020</a>].</div></li></ul><p>
<b>Sibs of a proband</b>
</p><ul><li class="half_rhythm"><div>If both parents are known to be heterozygous for an <i>LZTR1</i> pathogenic variant, each sib of an affected individual has at conception a 25% chance of inheriting two pathogenic variants and being affected, a 50% chance of inheriting one <i>LZTR1</i> pathogenic variant and being heterozygous, and a 25% chance of inheriting neither familial pathogenic variant.</div></li><li class="half_rhythm"><div>Heterozygotes may be asymptomatic [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.johnston.2018.1175" role="button" aria-expanded="false" aria-haspopup="true">Johnston et al 2018</a>] or may have mild features of NS [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.jenkins.2020.e002690" role="button" aria-expanded="false" aria-haspopup="true">Jenkins et al 2020</a>].</div></li></ul><p><b>Offspring of a proband.</b> The offspring of an individual with NS are obligate heterozygotes for a pathogenic variant in <i>LZTR1</i>.</p><p><b>Other family members.</b> Each sib of the proband's parents is at a 50% risk of being heterozygous for an <i>LZTR1</i> pathogenic variant.</p><div id="noonan.Heterozygote_Detection"><h4>Heterozygote Detection</h4><p>Heterozygote detection for at-risk relatives requires prior identification of the <i>LZTR1</i> pathogenic variants in the family.</p></div></div><div id="noonan.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>
<b>Family planning</b>
</p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</div></li></ul><p><b>DNA banking.</b> Because it is likely that testing methodology and our understanding of genes, pathogenic mechanisms, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative pathogenic mechanism is unknown). For more information, see <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.huang.2022.389" role="button" aria-expanded="false" aria-haspopup="true">Huang et al [2022]</a>.</p></div><div id="noonan.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p>
<b>High a priori-risk pregnancy</b>
</p><ul><li class="half_rhythm"><div><b>Molecular genetic testing.</b> Once the NS-related pathogenic variant(s) have been identified in an affected family member, prenatal and preimplantation genetic testing are possible.</div></li><li class="half_rhythm"><div><b>Ultrasound examination.</b> For a pregnancy at 50% risk, high-resolution ultrasound examination is also possible. Prenatal features are nonspecific but may include polyhydramnios, hydronephrosis, pleural effusion, edema, cardiac defects, distended jugular lymphatic sacs, cystic hygroma, and increased nuchal translucency [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.myers.2014.2814" role="button" aria-expanded="false" aria-haspopup="true">Myers et al 2014</a>]. Cystic hygroma may be accompanied by scalp edema, polyhydramnios, pleural and pericardial effusions, ascites, and/or frank hydrops fetalis. The presence of these findings should suggest the diagnosis of NS. In addition, a search for a cardiac defect should be made; congenital heart disease is diagnosed prenatally in about 20% of cases [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.myers.2014.2814" role="button" aria-expanded="false" aria-haspopup="true">Myers et al 2014</a>]. Treatment of these pregnancy complications is the same as that in the general population.</div></li></ul><p><b>Low a priori-risk pregnancy</b> (i.e., a fetus at no known increased risk of NS). Although the ultrasonographic findings described suggest the diagnosis of NS in high-risk pregnancies, they are nonspecific and may be associated with cardiovascular defects or other chromosome and non-chromosome syndromes. In a retrospective analysis of 309 pregnancies with isolated increased nuchal translucency (&gt;99%ile) and no other reported ultrasound findings, four pregnancies were subsequently diagnosed with NS [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.pauta.2022.26" role="button" aria-expanded="false" aria-haspopup="true">Pauta et al 2022</a>]. Of 44 pregnancies with nonimmune hydrops fetalis enrolled in the Hydrops-Yielding Diagnostic Results of Prenatal Sequencing (HYDROPS) study, four were diagnosed with NS by trio exome analysis [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.alkouatly.2021.1325" role="button" aria-expanded="false" aria-haspopup="true">Al-Kouatly et al 2021</a>].</p></div></div><div id="noonan.Resources"><h2 id="_noonan_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/app4/">here</a>.</i></p>
<ul><li class="half_rhythm"><div>
<b> New England Regional Genetics Network </b>
</div><div><b>Phone:</b> 603-862-4320</div><div><b>Email:</b> info.negenetics@unh.edu</div><div>
<a href="https://www.negenetics.org/gemss/conditions/noonan-syndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Noonan <span class="term-highlight">Syndrome</span></a>
</div></li><li class="half_rhythm"><div>
<b>MedlinePlus</b>
</div><div>
<a href="https://medlineplus.gov/genetics/condition/noonan-syndrome/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Noonan <span class="term-highlight">syndrome</span></a>
</div></li><li class="half_rhythm"><div>
<b>Noonan <span class="term-highlight">Syndrome</span> Foundation</b>
</div><div><b>Email:</b> info@teamnoonan.org</div><div>
<a href="http://www.teamnoonan.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.teamnoonan.org</a>
</div></li><li class="half_rhythm"><div>
<b>RASopathies Network</b>
</div><div><b>Email:</b> info@rasopathiesnet.org</div><div>
<a href="http://rasopathiesnet.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.rasopathiesnet.org</a>
</div></li><li class="half_rhythm"><div>
<b>Human Growth Foundation</b>
</div><div>
<a href="https://www.hgfound.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hgfound.org</a>
</div></li><li class="half_rhythm"><div>
<b>MAGIC Foundation</b>
</div><div><b>Phone:</b> 800-362-4423</div><div><b>Email:</b> contactus@magicfoundation.org</div><div>
<a href="https://www.magicfoundation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.magicfoundation.org</a>
</div></li></ul>
</div><div id="noonan.Molecular_Genetics"><h2 id="_noonan_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —</i>ED.</p><div id="noonan.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Noonan <span class="term-highlight">Syndrome</span>: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/gene/673" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene">
<i>BRAF</i>
</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&amp;acc=673" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">7q34</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.uniprot.org/uniprot/P15056" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Serine/threonine-protein kinase B-raf</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://databases.lovd.nl/shared/genes/BRAF" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRAF database</a>
<br>
<a href="https://nseuronet.com/php/statistic.php?genotype=5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NSEuroNet database - BRAF</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BRAF" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRAF</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=BRAF[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRAF</a>
</td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/gene/3845" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene">
<i>KRAS</i>
</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&amp;acc=3845" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">12p12<wbr style="display:inline-block">​.1</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.uniprot.org/uniprot/P01116" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GTPase KRas</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://databases.lovd.nl/shared/genes/KRAS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRAS database</a>
<br>
<a href="https://nseuronet.com/php/statistic.php?genotype=3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NSEuroNet database - KRAS</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=KRAS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRAS</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=KRAS[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRAS</a>
</td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/gene/8216" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene">
<i>LZTR1</i>
</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&amp;acc=8216" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">22q11<wbr style="display:inline-block">​.21</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.uniprot.org/uniprot/Q8N653" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Leucine-zipper-like transcriptional regulator 1</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://databases.lovd.nl/shared/genes/LZTR1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LZTR1 @ LOVD</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=LZTR1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LZTR1</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=LZTR1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LZTR1</a>
</td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/gene/5604" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene">
<i>MAP2K1</i>
</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&amp;acc=5604" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">15q22<wbr style="display:inline-block">​.31</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.uniprot.org/uniprot/Q02750" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Dual specificity mitogen-activated protein kinase kinase 1</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.lovd.nl/MAP2K1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAP2K1 @ LOVD</a>
<br>
<a href="https://nseuronet.com/php/statistic.php?genotype=9" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NSEuroNet database - MAP2K1</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=MAP2K1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAP2K1</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=MAP2K1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAP2K1</a>
</td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/gene/22808" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene">
<i>MRAS</i>
</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&amp;acc=22808" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">3q22<wbr style="display:inline-block">​.3</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.uniprot.org/uniprot/O14807" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ras-related protein M-Ras</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=MRAS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MRAS</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=MRAS[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MRAS</a>
</td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/gene/4893" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene">
<i>NRAS</i>
</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&amp;acc=4893" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1p13<wbr style="display:inline-block">​.2</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.uniprot.org/uniprot/P01111" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GTPase NRas</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://databases.lovd.nl/shared/genes/NRAS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NRAS database</a>
<br>
<a href="http://structure.bmc.lu.se/idbase/NRASbase/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NRASbase: Mutation registry for Autoimmune lymphoproliferative <span class="term-highlight">syndrome</span> type IV</a>
<br>
<a href="https://nseuronet.com/php/statistic.php?genotype=4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NSEuroNet database - NRAS</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=NRAS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NRAS</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NRAS[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NRAS</a>
</td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/gene/5781" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene">
<i>PTPN11</i>
</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&amp;acc=5781" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">12q24<wbr style="display:inline-block">​.13</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.uniprot.org/uniprot/Q06124" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Tyrosine-protein phosphatase non-receptor type 11</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://databases.lovd.nl/shared/genes/PTPN11" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PTPN11 database</a>
<br>
<a href="http://structure.bmc.lu.se/idbase/PTPN11base/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PTPN11base: Database for pathogenic mutations in the SHP-2 SH2 domain</a>
<br>
<a href="https://nseuronet.com/php/statistic.php?genotype=7" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NSEuroNet database - PTPN11</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PTPN11" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PTPN11</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PTPN11[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PTPN11</a>
</td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/gene/5894" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene">
<i>RAF1</i>
</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&amp;acc=5894" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">3p25<wbr style="display:inline-block">​.2</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.uniprot.org/uniprot/P04049" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RAF proto-oncogene serine/threonine-protein kinase</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://nseuronet.com/php/statistic.php?genotype=6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NSEuroNet database - RAF1</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RAF1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RAF1</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=RAF1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RAF1</a>
</td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/gene/5922" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene">
<i>RASA2</i>
</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&amp;acc=5922" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">3q23</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.uniprot.org/uniprot/Q15283" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ras GTPase-activating protein 2</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RASA2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RASA2</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=RASA2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RASA2</a>
</td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/gene/6016" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene">
<i>RIT1</i>
</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&amp;acc=6016" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q22</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.uniprot.org/uniprot/Q92963" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GTP-binding protein Rit1</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://nseuronet.com/php/statistic.php?genotype=13" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NSEuroNet database - RIT1</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RIT1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RIT1</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=RIT1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RIT1</a>
</td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/gene/22800" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene">
<i>RRAS2</i>
</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&amp;acc=22800" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">11p15<wbr style="display:inline-block">​.2</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.uniprot.org/uniprot/P62070" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ras-related protein R-Ras2</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://databases.lovd.nl/shared/genes/RRAS2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RRAS2 database</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RRAS2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RRAS2</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=RRAS2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RRAS2</a>
</td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/gene/6654" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene">
<i>SOS1</i>
</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&amp;acc=6654" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2p22<wbr style="display:inline-block">​.1</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.uniprot.org/uniprot/Q07889" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Son of sevenless homolog 1</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://databases.lovd.nl/shared/genes/SOS1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SOS1 database</a>
<br>
<a href="https://nseuronet.com/php/statistic.php?genotype=8" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NSEuroNet database - SOS1</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SOS1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SOS1</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SOS1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SOS1</a>
</td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/gene/6655" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene">
<i>SOS2</i>
</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&amp;acc=6655" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">14q21<wbr style="display:inline-block">​.3</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.uniprot.org/uniprot/Q07890" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Son of sevenless homolog 2</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SOS2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SOS2</a>
</td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SOS2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SOS2</a>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="noonan.TFA.1"><p class="no_margin">Data are compiled from the following standard references: gene from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
chromosome locus from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="https://www.ncbi.nlm.nih.gov/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="noonan.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Noonan <span class="term-highlight">Syndrome</span> (<a href="https://www.ncbi.nlm.nih.gov/omim/163950,164757,164760,164790,176872,176876,182530,190070,600098,600574,601247,601589,605275,608435,609591,609942,610733,611553,613224,613706,615355,616559,616564,618499,618624" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/163950" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">163950</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN <span class="term-highlight">SYNDROME</span> 1; NS1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/164757" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">164757</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">B-RAF PROTOONCOGENE, SERINE/THREONINE KINASE; BRAF</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/164760" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">164760</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RAF1 PROTOONCOGENE, SERINE/THREONINE KINASE; RAF1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/164790" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">164790</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NRAS PROTOONCOGENE, GTPase; NRAS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/176872" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">176872</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1; MAP2K1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/176876" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">176876</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 11; PTPN11</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/182530" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">182530</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SOS RAS/RAC GUANINE NUCLEOTIDE EXCHANGE FACTOR 1; SOS1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/190070" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">190070</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">KRAS PROTOONCOGENE, GTPase; KRAS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/600098" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600098</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RELATED RAS VIRAL ONCOGENE HOMOLOG 2; RRAS2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/600574" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600574</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LEUCINE ZIPPER-LIKE TRANSCRIPTIONAL REGULATOR 1; LZTR1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/601247" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601247</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SOS RAS/RAC GUANINE NUCLEOTIDE EXCHANGE FACTOR 2; SOS2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/601589" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601589</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RAS p21 PROTEIN ACTIVATOR 2; RASA2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/605275" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605275</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN <span class="term-highlight">SYNDROME</span> 2; NS2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/608435" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">608435</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MUSCLE RAS VIRAL ONCOGENE HOMOLOG; MRAS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/609591" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609591</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RIC-LIKE PROTEIN WITHOUT CAAX MOTIF 1; RIT1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/609942" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609942</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN <span class="term-highlight">SYNDROME</span> 3; NS3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/610733" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">610733</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN <span class="term-highlight">SYNDROME</span> 4; NS4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/611553" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">611553</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN <span class="term-highlight">SYNDROME</span> 5; NS5</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/613224" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613224</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN <span class="term-highlight">SYNDROME</span> 6; NS6</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/613706" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613706</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN <span class="term-highlight">SYNDROME</span> 7; NS7</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/615355" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">615355</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN <span class="term-highlight">SYNDROME</span> 8; NS8</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/616559" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">616559</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN <span class="term-highlight">SYNDROME</span> 9; NS9</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/616564" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">616564</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN <span class="term-highlight">SYNDROME</span> 10; NS10</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/618499" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">618499</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN <span class="term-highlight">SYNDROME</span> 11; NS11</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="https://www.ncbi.nlm.nih.gov/omim/618624" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">618624</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN <span class="term-highlight">SYNDROME</span> 12; NS12</td></tr></tbody></table></div></div><div id="noonan.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>The genes implicated in Noonan <span class="term-highlight">syndrome</span> are part of or interact with the Ras/MAPK pathway. This pathway is a widely important signal transduction pathway. Growth factors, cytokines, hormones, and other extracellular ligands stimulate cell differentiation, proliferation, metabolism, and survival. Adaptor proteins are recruited and form a complex that converts inactive, GDP-bound RAS to its active GTP-bound form. This leads to downstream activation of the RAF-MEK-ERK pathway via sequential phosphorylation, culminating in activated ERK entering the nucleus and altering gene transcription. Noonan <span class="term-highlight">syndrome</span> pathogenic variants usually enhance signal flow through this pathway [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.roberts.2013.333" role="button" aria-expanded="false" aria-haspopup="true">Roberts et al 2013</a>].</p><div id="noonan.T.noonan_syndrome_mechanism_of_di" class="table"><h3><span class="label">Table 9. </span></h3><div class="caption"><p>Noonan <span class="term-highlight">Syndrome</span>: Mechanism of Disease Causation</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.noonan_syndrome_mechanism_of_di/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.T.noonan_syndrome_mechanism_of_di_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&nbsp;<sup>1</sup></th><th id="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mechanism</th><th id="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comment/Reference</th></tr></thead><tbody><tr><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>BRAF</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Gain of<br>function</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.sarkozy.2009.695" role="button" aria-expanded="false" aria-haspopup="true">Sarkozy et al [2009]</a>
</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>KRAS</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
<i>LZTR1</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gain of<br>function</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For heterozygous pathogenic variants that lead to autosomal dominant <i>LZTR1</i>-related Noonan <span class="term-highlight">syndrome</span> [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.motta.2019.1007" role="button" aria-expanded="false" aria-haspopup="true">Motta et al 2019</a>]</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Loss of<br>function</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Recessive variants typically influence protein synthesis/stability or subcellular localization [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.motta.2019.1007" role="button" aria-expanded="false" aria-haspopup="true">Motta et al 2019</a>].</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>MAP2K1</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_2" rowspan="10" colspan="1" style="text-align:left;vertical-align:middle;">Gain of<br>function</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.cirstea.2010.27" role="button" aria-expanded="false" aria-haspopup="true">Cirstea et al [2010]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.runtuwene.2011.393" role="button" aria-expanded="false" aria-haspopup="true">Runtuwene et al [2011]</a></td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>MRAS</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.higgins.2017.e91225" role="button" aria-expanded="false" aria-haspopup="true">Higgins et al [2017]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.motta.2020.1772" role="button" aria-expanded="false" aria-haspopup="true">Motta et al [2020]</a></td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>NRAS</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>PTPN11</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>RAF1</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.pandit.2007.1007" role="button" aria-expanded="false" aria-haspopup="true">Pandit et al [2007]</a>
</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>RASA2</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.chen.2014b.11473" role="button" aria-expanded="false" aria-haspopup="true">Chen et al [2014b]</a>
</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>RIT1</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.aoki.2013.173" role="button" aria-expanded="false" aria-haspopup="true">Aoki et al [2013]</a>
</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>RRAS</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.chen.2014b.11473" role="button" aria-expanded="false" aria-haspopup="true">Chen et al [2014b]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.flex.2014.4315" role="button" aria-expanded="false" aria-haspopup="true">Flex et al [2014]</a></td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>SOS1</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.roberts.2007.70" role="button" aria-expanded="false" aria-haspopup="true">Roberts et al [2007]</a>
</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>SOS2</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_mechanism_of_di_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.chen.2014b.11473" role="button" aria-expanded="false" aria-haspopup="true">Chen et al [2014b]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.yamamoto.2015.413" role="button" aria-expanded="false" aria-haspopup="true">Yamamoto et al [2015]</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.lissewski.2021.51" role="button" aria-expanded="false" aria-haspopup="true">Lissewski et al [2021]</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="noonan.TF.9.1"><p class="no_margin">Genes from <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-ob="figobnoonanTmoleculargenetictestingused">Table 1</a> in alphabetic order</p></div></dd></dl></div></div></div><div id="noonan.T.noonan_syndrome_notable_pathoge" class="table"><h3><span class="label">Table 10. </span></h3><div class="caption"><p>Noonan <span class="term-highlight">Syndrome</span>: Notable Pathogenic Variants by Gene</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.noonan_syndrome_notable_pathoge/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.T.noonan_syndrome_notable_pathoge_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&nbsp;<sup>1</sup></th><th id="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th><th id="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted<br>Protein Change</th><th id="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment [Reference]</th></tr></thead><tbody><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_1" rowspan="27" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
<i>PTPN11</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/33356176?report=genbank" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002834<wbr style="display:inline-block">​.3</a>
<br>
<a href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&amp;id=33356177" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002825<wbr style="display:inline-block">​.3</a>
</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.179_181delGTG</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly60del</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.yoshida.2004.63" role="button" aria-expanded="false" aria-haspopup="true">Yoshida et al [2004]</a>
</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.181_183delGAT</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp61del</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.lee.2005b.7" role="button" aria-expanded="false" aria-haspopup="true">Lee et al [2005b]</a>
</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_2" rowspan="25" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/33356176?report=genbank" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002834<wbr style="display:inline-block">​.5</a>
<br>
<a href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&amp;id=33356177" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002825<wbr style="display:inline-block">​.3</a>
</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.172A&gt;G</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn58Asp</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_5" rowspan="25" colspan="1" style="text-align:left;vertical-align:middle;">NS &amp; JMML&nbsp;<sup>2</sup></td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.174C&gt;G</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn58Lys</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.182A&gt;G</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp61Gly</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.184T&gt;G</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr62Asp</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.188A&gt;G</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr63Cys</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.214G&gt;A</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala72Thr</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.214G&gt;T</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala72Ser</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.215C&gt;G</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala72Gly</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.218C&gt;T</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr73Ile</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.227A&gt;T</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu76Val</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.228G&gt;T</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu76Asp</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.236A&gt;G</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln79Arg</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.417G&gt;C</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu139Asp</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.417G&gt;T</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu139Asp</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.794G&gt;A</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg265Gln</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.836A&gt;C</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr279Ser</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.853T&gt;C</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe285Leu</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.922A&gt;G&nbsp;<sup>3</sup></td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn308Asp&nbsp;<sup>3</sup></td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.923A&gt;G</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn308Ser</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1403C&gt;T</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr468Met</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1504T&gt;G</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser502Ala</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1504T&gt;A</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser502Thr</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1507G&gt;A</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly503Arg</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1507G&gt;C</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly503Arg</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1510A&gt;G</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Met504Val</td></tr><tr><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<i>RAF1</i>
</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_002880.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002880<wbr style="display:inline-block">​.4</a>
<br>
<a href="https://www.ncbi.nlm.nih.gov/protein/NP_002871.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002871<wbr style="display:inline-block">​.1</a>
</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.770C&gt;T</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser257Leu</td><td headers="hd_h_noonan.T.noonan_syndrome_notable_pathoge_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2 persons w/infantile fatal pulmonary hypertension&nbsp;<sup>4</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="https://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block">​.hgvs.org</a>). See <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt></dt><dd><div><p class="no_margin">JMML = juvenile myelomonocytic leukemia; NS = Noonan <span class="term-highlight">syndrome</span></p></div></dd><dt>1. </dt><dd><div id="noonan.TF.10.1"><p class="no_margin">Genes from <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/table/noonan.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-ob="figobnoonanTmoleculargenetictestingused">Table 1</a> in alphabetic order</p></div></dd><dt>2. </dt><dd><div id="noonan.TF.10.2"><p class="no_margin">Curated from Clinvar; included variants are those classified as pathogenic or likely pathogenic with both Noonan <span class="term-highlight">syndrome</span> and JMML as listed conditions for the variant [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.grant.2018.1485" role="button" aria-expanded="false" aria-haspopup="true">Grant et al 2018</a>].</p></div></dd><dt>3. </dt><dd><div id="noonan.TF.10.3"><p class="no_margin">Less likely to be associated with learning issues [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.jongmans.2004.56" role="button" aria-expanded="false" aria-haspopup="true">Jongmans et al 2004</a>]</p></div></dd><dt>4. </dt><dd><div id="noonan.TF.10.4"><p class="no_margin">
<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.hopper.2015.882" role="button" aria-expanded="false" aria-haspopup="true">Hopper et al [2015]</a>
</p></div></dd></dl></div></div></div></div><div id="noonan.Cancer_and_Benign_Tumors"><h3>Cancer and Benign Tumors</h3><p>Sporadic tumors (including leukemia and solid tumors) occurring as single tumors in the absence of any other findings of Noonan <span class="term-highlight">syndrome</span> may contain a somatic nucleotide variant in <i>PTPN11</i>, <i>KRAS</i>, <i>LZTR1</i>, <i>MRAS</i>, <i>NRAS</i>, <i>BRAF</i>, or <i>MAP2K1</i> that is not present in the germline; thus, predisposition to these tumors is not heritable. See <a href="https://cancer.sanger.ac.uk/cosmic" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Catalogue of Somatic Mutations in Cancer</a>.</p><ul><li class="half_rhythm"><div>Leukemia and solid tumors. Juvenile myelomonocytic leukemia (JMML) accounts for one third of myelodysplastic <span class="term-highlight">syndrome</span> (MDS) and about 2% of leukemia. Pathogenic variants in <i>NRAS</i>, <i>KRAS</i>, and <i>NF1</i> have been shown to deregulate the RAS-MAPK pathway leading to JMML in about 40% of affected individuals. Somatic pathogenic variants in exons 3 and 13 of <i>PTPN11</i> have been demonstrated in 34% of individuals with JMML in one cohort [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.tartaglia.2003.148" role="button" aria-expanded="false" aria-haspopup="true">Tartaglia et al 2003</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.tartaglia.2004.307" role="button" aria-expanded="false" aria-haspopup="true">Tartaglia et al 2004</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.hasle.2009.8" role="button" aria-expanded="false" aria-haspopup="true">Hasle 2009</a>].</div></li><li class="half_rhythm"><div>Pathogenic variants in <i>PTPN11</i> exon 3, were also found in 19% of children with MDS with an excess of blast cells, which often evolves into acute myeloid leukemia (AML) and is associated with poor prognosis. Nonsyndromic AML, especially the monocyte subtype FAB-MD, can be caused by <i>PTPN11</i> pathogenic variants. These pathogenic variants cause a gain of function in tyrosine-protein phosphatase non-receptor type II (SHP-2), likely leading to an early initiating lesion in JMML oncogenesis with increased cell proliferation ‒ attributable in part to prolonged activation of the RAS-MAPK pathway.</div></li><li class="half_rhythm"><div>The spectrum of leukemogenesis associated with <i>PTPN11</i> pathogenic variants has been extended to include childhood acute lymphoblastic leukemia (ALL). Pathogenic variants were observed in 8% of individuals with B-cell precursor ALL, but not among children with T-lineage ALL [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.tartaglia.2004.307" role="button" aria-expanded="false" aria-haspopup="true">Tartaglia et al 2004</a>]. Additionally, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.bentiresalj.2004.8816" role="button" aria-expanded="false" aria-haspopup="true">Bentires-Alj et al [2004]</a> described SHP-2-activating <i>PTPN11</i> pathogenic variants in solid tumors including breast, lung, and gastric neoplasms and neuroblastoma.</div></li><li class="half_rhythm"><div>Somatic <i>RAF1</i> nucleotide variants have only rarely been found in cancer; most of these cancer-causing variants do not cluster in the regions that are germline mutational hot spots in Noonan <span class="term-highlight">syndrome</span> [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.pandit.2007.1007" role="button" aria-expanded="false" aria-haspopup="true">Pandit et al 2007</a>].</div></li><li class="half_rhythm"><div><i>NRAS</i> variants are commonly observed in somatic cancer; they occur in regions different from germline <i>NRAS</i> variants that cause Noonan <span class="term-highlight">syndrome</span>.</div></li><li class="half_rhythm"><div><i>MAP2K1</i> somatic variants have been reported in ovarian cancer [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.estep.2007.e1279" role="button" aria-expanded="false" aria-haspopup="true">Estep et al 2007</a>] and lung cancer [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.marks.2008.5524" role="button" aria-expanded="false" aria-haspopup="true">Marks et al 2008</a>].</div></li><li class="half_rhythm"><div>Somatic <i>SOS1</i> pathogenic variants have not been found in cancer.</div></li><li class="half_rhythm"><div>Recent studies have identified somatic <i>RIT1</i> pathogenic variants in lung adenocarcinoma and myeloproliferative or mixed myelodysplastic/myeloproliferative neoplasms [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.berger.2014.4418" role="button" aria-expanded="false" aria-haspopup="true">Berger et al 2014</a>, <a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.cancer_genome_atlas_research_network.2014.543" role="button" aria-expanded="false" aria-haspopup="true">Cancer Genome Atlas Research Network 2014</a>].</div></li><li class="half_rhythm"><div>The somatic p.Gly248Arg pathogenic variant in <i>LZTR1</i> has been identified in melanoma, glioblastoma, and colorectal cancers (<a href="https://cancer.sanger.ac.uk/cosmic" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COSMIC</a> database).</div></li></ul></div></div><div id="noonan.Chapter_Notes"><h2 id="_noonan_Chapter_Notes_">Chapter Notes</h2><div id="noonan.Author_Notes"><h3>Author Notes</h3><p>Amy E Roberts, MD, FACMG</p><p>Department of Cardiology and Division of Genetics, Department of Pediatrics, Boston Children’s Hospital, Boston, MA</p><p>Email: amy.roberts@cardio.chboston.org</p><p>Website: <a href="https://www.childrenshospital.org/directory/amy-roberts" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.childrenshospital.org/directory/amy-roberts</a></p><p>Dr Roberts is trained in both clinical genetics and pediatrics. Her research focuses on genotype phenotype correlations and gene discovery in Noonan <span class="term-highlight">syndrome</span> and other RASopathies. She is a member of the <a href="https://rasopathiesnet.org/about/research-advisory-board/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Scientific Advisory Board of RASopathies Network</a> and the <a href="https://www.cfcsyndrome.org/medical-advisory-board" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Medical Advisory Board of CFC international</a>.</p></div><div id="noonan.Acknowledgments"><h3>Acknowledgments</h3><p>Our understanding of Noonan <span class="term-highlight">syndrome</span> is deeply informed by the life's work of the late Dr Jacqueline A Noonan [<a class="bk_pop" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#" data-bk-pop-href="#noonan.REF.gelb.2020.1498" role="button" aria-expanded="false" aria-haspopup="true">Gelb et al 2020</a>], who first described the diagnosis in 1963. The author would like to acknowledge the original author of this <i>GeneReview</i>, Judith Allanson, and the mentorship, collaboration, and collegiality of leaders in the field, including Bruce Gelb, Bryan Hall, Maria Kontaridis, Raju Kucherlapati, Mary Ella Pierpont, Rene Pierpont, Alicia Romano, Marco Tartaglia, Ineke van der Burgt, and Martin Zenker. Finally, Dr Roberts would like to thank the leadership of the <a href="https://rasopathiesnet.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RASopathies Network</a> and <a href="https://teamnoonan.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Noonan <span class="term-highlight">Syndrome</span> Foundation</a> as well as the many families with Noonan <span class="term-highlight">syndrome</span> who have shared their children's experiences in clinic, in research, and at family meetings for their selflessness and advocacy without which much of this work would not have been possible.</p></div><div id="noonan.Author_History"><h3>Author History</h3><p>Judith E Allanson, MD; Children's Hospital of Eastern Ontario (2001-2021)</p><p>Amy E Roberts, MD (2001-present)</p></div><div id="noonan.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>17 February 2022 (aa) Revision: <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/eccl/">encephalocraniocutaneous lipomatosis</a> added to <a href="https://www.ncbi.nlm.nih.gov/books/NBK1124/?report=printable#noonan.Genetically_Related_Allelic_Disor">Genetically Related Disorders</a></div></li><li class="half_rhythm"><div>16 December 2021 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>8 August 2019 (ma) Revision: pathogenic variants in <i>LZTR1</i> associated with autosomal dominant and autosomal recessive Noonan <span class="term-highlight">syndrome</span></div></li><li class="half_rhythm"><div>25 February 2016 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>4 August 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 October 2008 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>6 September 2007 (cd) Revision: mutations in <i>RAF1</i> associated with Noonan <span class="term-highlight">syndrome</span></div></li><li class="half_rhythm"><div>22 December 2006 (cd) Revision: <i>SOS1</i> mutations responsible for some cases of Noonan <span class="term-highlight">syndrome</span>; clinical testing available</div></li><li class="half_rhythm"><div>22 May 2006 (cd) Revision: prenatal testing for Noonan <span class="term-highlight">syndrome</span> caused by <i>KRAS</i> mutations clinically available</div></li><li class="half_rhythm"><div>16 May 2006 (cd) Revision: <i>KRAS</i> testing clinically available</div></li><li class="half_rhythm"><div>1 May 2006 (ja) Revision: mutations in <i>KRAS</i> cause Noonan <span class="term-highlight">syndrome</span></div></li><li class="half_rhythm"><div>9 March 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>17 December 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 November 2001 (me) Review posted live</div></li><li class="half_rhythm"><div>2 August 2001 (ja) Original submission</div></li></ul></div></div><div id="noonan.References"><h2 id="_noonan_References_">References</h2><div id="noonan.Published_Guidelines__Consensus_S"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div>Noonan <span class="term-highlight">Syndrome</span> Guideline Development Group. Management of Noonan <span class="term-highlight">syndrome</span> – a clinical guideline (pdf). University of Manchester: DYSCERNE. Available <a href="https://rasopathiesnet.org/wp-content/uploads/2014/01/265_Noonan_Guidelines.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2010. Accessed 6-7-23.</div></li><li class="half_rhythm"><div>Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan <span class="term-highlight">syndrome</span>. Lancet. 2013;381:333-42. [<a href="https://pubmed.ncbi.nlm.nih.gov/23312968/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed</a>]</div></li><li class="half_rhythm"><div>Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, Roberts AE, Robinson W, Takemoto CM, Noonan JA. Noonan <span class="term-highlight">syndrome</span>: clinical features, diagnosis, and management guidelines. Pediatrics. 2010;126:746-59. [<a href="https://pubmed.ncbi.nlm.nih.gov/20876176/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed</a>]</div></li></ul></div><div id="noonan.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.alfieri.2021.233">Alfieri
P, Cumbo
F, Serra
G, Trasolini
M, Frattini
C, Scibelli
F, Licchelli
S, Cirillo
F, Caciolo
C, Casini
MP, D'Amico
A, Tartaglia
M, Digilio
MC, Capolino
R, Vicari
S. Manic and depressive symptoms in children diagnosed with Noonan <span class="term-highlight">syndrome</span>.
Brain Sci.
2021;11:233.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918671/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7918671</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33668418" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 33668418</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.alkouatly.2021.1325">Al-Kouatly
HB, Makhamreh
MM, Rice
SM, Smith
K, Harman
C, Quinn
A, Valcarcel
BN, Firman
B, Liu
R, Hegde
M, Critchlow
E, Berger
SI. High diagnosis rate for nonimmune hydrops fetalis with prenatal clinical exome from the Hydrops-Yielding Diagnostic Results of Prenatal Sequencing (HYDROPS) Study.
Genet Med.
2021;23:1325-33.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/33686258" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 33686258</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.altm_ller.2017.823">Altmüller
F, Lissewski
C, Bertola
D, Flex
E, Stark
Z, Spranger
S, Baynam
G, Buscarilli
M, Dyack
S, Gillis
J, Yntema
HG, Pantaleoni
F, van Loon
RL, MacKay
S, Mina
K, Schanze
I, Tan
TY, Walsh
M, White
SM, Niewisch
MR, García-Miñaúr
S, Plaza
D, Ahmadian
MR, Cavé
H, Tartaglia
M, Zenker
M. Genotype and phenotype spectrum of NRAS germline variants.
Eur J Hum Genet.
2017;25:823-31.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520077/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5520077</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28594414" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28594414</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.andelfinger.2019.2237">Andelfinger
G, Marquis
C, Raboisson
MJ, Théoret
Y, Waldmüller
S, Wiegand
G, Gelb
BD, Zenker
M, Delrue
MA, Hofbeck
M. Hypertrophic cardiomyopathy in Noonan <span class="term-highlight">syndrome</span> treated by MEK-inhibition.
J Am Coll Cardiol.
2019;73:2237-9.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916648/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6916648</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31047013" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31047013</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.aoki.2013.173">Aoki
Y, Niihori
T, Banjo
T, Okamoto
N, Mizuno
S, Kurosawa
K, Ogata
T, Takada
F, Yano
M, Ando
T, Hoshika
T, Barnett
C, Ohashi
H, Kawame
H, Hasegawa
T, Okutani
T, Nagashima
T, Hasegawa
S, Funayama
R, Nagashima
T, Nakayama
K, Inoue
S, Watanabe
Y, Ogura
T, Matsubara
Y.
Gain-of-function mutations in RIT1 cause Noonan <span class="term-highlight">syndrome</span>, a RAS/MAPK pathway <span class="term-highlight">syndrome</span>.Am J Hum Genet.
2013;93:173-80.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710767/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3710767</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23791108" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23791108</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.aoki.2016.33">Aoki
Y, Niihori
T, Inoue
SI, Matsubara
Y. Recent advances in RASopathies.
J Hum Genet.
2016;61:33-9.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/26446362" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26446362</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.armour.2008.249">Armour
CM, Allanson
JE (2008) Further delineation of cardio-facio-cutaneous <span class="term-highlight">syndrome</span>: clinical features of 38 individuals with proven mutations.
J Med Genet
45:249-54
 [<a href="https://pubmed.ncbi.nlm.nih.gov/18039946" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18039946</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.beneteau.2009.1216">Beneteau
C, Cavé
H, Moncla
A, Dorison
N, Munnich
A, Verloes
A, Leheup
B (2009) SOS1 and PTPN11 mutations in five cases of Noonan <span class="term-highlight">syndrome</span> with multiple giant cell lesions.
Eur J Hum Genet.
17:1216-21.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2986637/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2986637</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19352411" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19352411</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.bentiresalj.2004.8816">Bentires-Alj
M, Paez
JG, David
FS, Keilhack
H, Halmos
B, Naoki
K, Maris
JM, Richardson
A, Bardelli
A, Sugarbaker
DJ, Richards
WG, Du
J, Girard
L, Minna
JD, Loh
ML, Fisher
DE, Velculescu
VE, Vogelstein
B, Meyerson
M, Sellers
WR, Neel
BG (2004) Activating mutations of the Noonan <span class="term-highlight">syndrome</span>-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Cancer Res
64:8816-20
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15604238" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15604238</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.berger.2014.4418">Berger
AH, Imielinski
M, Duke
F, Wala
J, Kaplan
N, Shi
GX, Andres
DA, Meyerson
M. Oncogenic RIT1 mutations in lung adenocarcinoma.
Oncogene.
2014;33:4418-23.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150988/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4150988</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24469055" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24469055</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.bertola.2005.242">Bertola
DR, Pereira
AC, Passetti
F, de Oliveira
PS, Messiaen
L, Gelb
BD, Kim
CA, Krieger
JE (2005) Neurofibromatosis-Noonan <span class="term-highlight">syndrome</span>: molecular evidence of the concurrence of both disorders in a patient.
Am J Med Genet A.
136:242-5.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15948193" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15948193</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.bertola.2014.2952">Bertola
DR, Yamamoto
GL, Almeida
TF, Buscarilli
M, Jorge
AA, Malaquias
AC, Kim
CA, Takahashi
VN, Passos-Bueno
MR, Pereira
AC. Further evidence of the importance of RIT1 in Noonan <span class="term-highlight">syndrome</span>.
Am J Med Genet A.
2014;164A:2952-7.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25124994" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25124994</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.brasil.2010.425">Brasil
AS, Pereira
AC, Wanderley
LT, Kim
CA, Malaquias
AC, Jorge
AA, Krieger
JE, Bertola
DR. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
Genet Test Mol Biomarkers.
2010;14:425-32.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/20578946" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20578946</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.briggs.2012.167">Briggs
BJ, Dickerman
JD. Bleeding disorders in Noonan <span class="term-highlight">syndrome</span>.
Pediatr Blood Cancer.
2012;58:167-72.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/22012616" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22012616</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.briggs.2020.154">Briggs
B, Savla
D, Ramchandar
N, Dimmock
D, Le
D, Thornburg
CD. The evaluation of hematologic screening and perioperative management in patients with Noonan <span class="term-highlight">syndrome</span>: a retrospective chart review.
J Pediatr.
2020;220:154-8.e6.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/32111381" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32111381</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.cancer_genome_atlas_research_network.2014.543">Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma.
Nature.
2014;511:543-50.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231481/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4231481</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25079552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25079552</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.capri.2019.1223">Capri
Y, Flex
E, Krumbach
OHF, Carpentieri
G, Cecchetti
S, Lißewski
C, Rezaei Adariani
S, Schanze
D, Brinkmann
J, Piard
J, Pantaleoni
F, Lepri
FR, Goh
ES, Chong
K, Stieglitz
E, Meyer
J, Kuechler
A, Bramswig
NC, Sacharow
S, Strullu
M, Vial
Y, Vignal
C, Kensah
G, Cuturilo
G, Kazemein Jasemi
NS, Dvorsky
R, Monaghan
KG, Vincent
LM, Cavé
H, Verloes
A, Ahmadian
MR, Tartaglia
M, Zenker
M. Activating mutations in RRAS2 are a rare cause of Noonan s<span class="term-highlight">yndrome.</span>
Am J Hum Genet.
2019;104:1223-32,
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562003/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6562003</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31130282" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31130282</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.chen.2014a.28">Chen
JL, Zhu
X, Zhao
TL, Wang
J, Yang
YF, Tan
ZP. Rare copy number variations containing genes involved in RASopathies: deletion of SHOC2 and duplication of PTPN11.
Mol Cytogenet.
2014a;7:28.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031927/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4031927</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24739123" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24739123</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.chen.2014b.11473">Chen
PC, Yin
J, Yu
HW, Yuan
T, Fernandez
M, Yung
CK, Trinh
QM, Peltekova
VD, Reid
JG, Tworog-Dube
E, Morgan
MB, Muzny DM6, Stein L, McPherson JD, Roberts AE, Gibbs RA, Neel BG, Kucherlapati R. Next-generation sequencing identifies rare variants associated with Noonan <span class="term-highlight">syndrome</span>.
Proc Natl Acad Sci U S A.
2014b;111:11473-8.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128129/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4128129</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25049390" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25049390</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.cirstea.2010.27">Cirstea
IC, Kutsche
K, Dvorsky
R, Gremer
L, Carta
C, Horn
D, Roberts
AE, Lepri
F, Merbitz-Zahradnik
T, König
R, Kratz
CP, Pantaleoni
F, Dentici
ML, Joshi
VA, Kucherlapati
RS, Mazzanti
L, Mundlos
S, Patton
MA, Silengo
MC, Rossi
C, Zampino
G, Digilio
C, Stuppia
L, Seemanova
E, Pennacchio
LA, Gelb
BD, Dallapiccola
B, Wittinghofer
A, Ahmadian
MR, Tartaglia
M, Zenker
M (2010) A restricted spectrum of NRAS mutations causes Noonan <span class="term-highlight">syndrome</span>.
Nat Genet
42:27-9.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118669/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3118669</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19966803" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19966803</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.colley.1996.59">Colley
A, Donnai
D, Evans
DG (1996) Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis.
Clin Genet.
49:59-64.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/8740913" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8740913</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.cordeddu.2009.1022">Cordeddu
V, Di Schiavi
E, Pennacchio
LA, Ma'ayan
A, Sarkozy
A, Fodale
V, Cecchetti
S, Cardinale
A, Martin
J, Schackwitz
W, Lipzen
A, Zampino
G, Mazzanti
L, Digilio
MC, Martinelli
S, Flex
E, Lepri
F, Bartholdi
D, Kutsche
K, Ferrero
GB, Anichini
C, Selicorni
A, Rossi
C, Tenconi
R, Zenker
M, Merlo
D, Dallapiccola
B, Iyengar
R, Bazzicalupo
P, Gelb
BD, Tartaglia
M (2009) Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like <span class="term-highlight">syndrome</span> with loose anagen hair.
Nat Genet.
41:1022-6.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2765465/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2765465</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19684605" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19684605</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.cordeddu.2015.1080">Cordeddu
V, Yin
JC, Gunnarsson
C, Virtanen
C, Drunat
S, Lepri
F, De Luca
A, Rossi
C, Ciolfi
A, Pugh
TJ, Bruselles
A, Priest
JR, Pennacchio
LA, Lu
Z, Danesh
A, Quevedo
R, Hamid
A, Martinelli
S, Pantaleoni
F, Gnazzo
M, Daniele
P, Lissewski
C, Bocchinfuso
G, Stella
L, Odent
S, Philip
N, Faivre
L, Vlckova
M, Seemanova
E, Digilio
C, Zenker
M, Zampino
G, Verloes
A, Dallapiccola
B, Roberts
AE, Cavé
H, Gelb
BD, Neel
BG, Tartaglia
M. Activating mutations affecting the Dbl homology domain of SOS2 cause Noonan <span class="term-highlight">syndrome</span>.
Hum Mutat.
2015;36:1080-7.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604019/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4604019</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26173643" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26173643</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.denayer.2010.242">Denayer
E, Devriendt
K, de Ravel
T, Van Buggenhout
G, Smeets
E, Francois
I, Sznajer
Y, Craen
M, Leventopoulos
G, Mutesa
L, Vandecasseye
W, Massa
G, Kayserili
H, Sciot
R, Fryns
JP, Legius
E (2010) Tumor spectrum in children with Noonan <span class="term-highlight">syndrome</span> and SOS1 or RAF1 mutations.
Genes Chromosomes Cancer.
49:242-52.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/19953625" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19953625</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.derbent.2010.2768">Derbent
M, Oncel
Y, Tokel
K, Varan
B, Haberal
A, Yazici
AC, Legius
E, Ozbek
N (2010). Clinical and hematological findings in Noonan <span class="term-highlight">syndrome</span> patients with PTPN11 mutations.
Am J Med Genet
152A:2768-74.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/20954246" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20954246</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.dori.2020.e20200167">Dori
Y, Smith
C, Pinto
E, Snyder
K, March
ME, Hakonarson
H, Belasco
J. Severe lymphatic disorder resolved with MEK inhibition in a patient with Noonan <span class="term-highlight">syndrome</span> and SOS1 mutation.
Pediatrics.
2020;146:e20200167.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/33219052" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 33219052</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.ejarque.2015.408">Ejarque
I, Millán-Salvador
JM, Oltra
S, Pesudo-Martínez
JV, Beneyto
M, Pérez-Aytés
A. Arnold-Chiari malformation in Noonan <span class="term-highlight">syndrome</span> and other syndromes of the RAS/MAPK pathway.
Rev Neurol.
2015;60:408-12.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25912702" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25912702</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.estep.2007.e1279">Estep
AL, Palmer
C, McCormick
F, Rauen
KA (2007) Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
PLoS One.
2:e1279.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2093994/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2093994</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18060073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18060073</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.flex.2014.4315">Flex
E, Jaiswal
M, Pantaleoni
F, Martinelli
S, Strullu
M, Fansa
EK, Caye
A, De Luca
A, Lepri
F, Dvorsky
R, Pannone
L, Paolacci
S, Zhang
SC, Fodale
V, Bocchinfuso
G, Rossi
C, Burkitt-Wright
EM, Farrotti
A, Stellacci
E, Cecchetti
S, Ferese
R, Bottero
L, Castro
S, Fenneteau
O, Brethon
B, Sanchez
M, Roberts
AE, Yntema
HG, Van Der Burgt
I, Cianci
P, Bondeson
ML, Cristina Digilio
M, Zampino
G, Kerr
B, Aoki
Y, Loh
ML, Palleschi
A, Di Schiavi
E, Carè
A, Selicorni
A, Dallapiccola
B, Cirstea
IC, Stella
L, Zenker
M, Gelb
BD, Cavé
H, Ahmadian
MR, Tartaglia
M. Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis.
Hum Mol Genet.
2014;23:4315-27.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103678/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4103678</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24705357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24705357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.fowlkes.2021.116060">Fowlkes
JL, Thrailkill
KM, Bunn
RC. RASopathies: The musculoskeletal consequences and their etiology and pathogenesis.
Bone.
2021;152:116060.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316423/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC8316423</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34144233" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 34144233</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.garren.2020.195">Garren
B, Stephan
M, Hogue
JS. NRAS associated RASopathy and embryonal rhabdomyosarcoma.
Am J Med Genet A.
2020;182:195-200.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/31697451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31697451</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.gelb.2020.1498">Gelb
BD, Newburger
JW, Roberts
AE, Williams
RG. In memoriam: Jaqueline A Noonan.
J Am Coll Cardiol.
2020:76:1498-500.</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.gelb.2015.13">Gelb
BD, Roberts
AE, Tartaglia
M. Cardiomyopathies in Noonan <span class="term-highlight">syndrome</span> and the other RASopathies.
Prog Pediatr Cardiol.
2015;39:13-19.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568836/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4568836</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26380542" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26380542</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.graham.2009.2122">Graham
JM
Jr, Kramer
N, Bejjani
BA, Thiel
CT, Carta
C, Neri
G, Tartaglia
M, Zenker
M (2009) Genomic duplication of PTPN11 is an uncommon cause of Noonan <span class="term-highlight">syndrome</span>.
Am J Med Genet
149A:2122-8.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768228/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2768228</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19760651" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19760651</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.grant.2018.1485">Grant
AR, Cushman
BJ, Cavé
H, Dillon
MW, Gelb
BD, Gripp
KW, Lee
JA, Mason-Suares
H, Rauen
KA, Tartaglia
M, Vincent
LM, Zenker
M. Assessing the gene-disease association of 19 genes with the RASopathies using the ClinGen gene curation framework.
Hum Mutat.
2018;39:1485-93.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326381/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6326381</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30311384" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30311384</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.gripp.2016.2237">Gripp
KW, Aldinger
KA, Bennett
JT, Baker
L, Tusi
J, Powell-Hamilton
N, Stabley
D, Sol-Church
K, Timms
AE, Dobyns
WB. A novel rasopathy caused by recurrent de novo missense mutations in PPP1CB closely resembles Noonan <span class="term-highlight">syndrome</span> with loose anagen hair.
Am J Med Genet A.
2016;170:2237-47.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134331/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5134331</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27264673" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27264673</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.guerin.2015.403">Guerin
A, So
J, Mireskandari
K, Jougeh-Doust
S, Chisholm
C, Klatt
R, Richer
J. Expanding the clinical spectrum of ocular anomalies in Noonan <span class="term-highlight">syndrome</span>: Axenfeld-anomaly in a child with PTPN11 mutation.
Am J Med Genet A.
2015;167A:403-6.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25425531" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25425531</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.hasle.2009.8">Hasle
H (2009) Malignant diseases in Noonan <span class="term-highlight">syndrome</span> and related disorders.
Horm Res
72:8-14.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/20029231" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20029231</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.hastings.2010.967">Hastings
R, Newbury-Ecob
R, Ng
A, Taylor
R.
A further patient with Noonan <span class="term-highlight">syndrome</span> due to a SOS1 mutation and rhabdomyosarcoma.
Genes Chromosomes Cancer.
2010;49:967-8.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/20607846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20607846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.hickey.2011.41">Hickey
EJ, Mehta
R, Elmi
M, Asoh
K, McCrindle
BW, Williams
WG, Manlhiot
C, Benson
L. Survival implications: hypertrophic cardiomyopathy in Noonan <span class="term-highlight">syndrome</span>.
Congenit Heart Dis
2011;6:41-7
 [<a href="https://pubmed.ncbi.nlm.nih.gov/21269411" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21269411</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.higgins.2017.e91225">Higgins
EM, Bos
JM, Mason-Suares
H, Tester
DJ, Ackerman
JP, MacRae
CA, Sol-Church
K, Gripp
KW, Urrutia
R, Ackerman
MJ. Elucidation of MRAS-mediated Noonan <span class="term-highlight">syndrome</span> with cardiac hypertrophy.
JCI Insight.
2017;2:e91225.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333962/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5333962</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28289718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28289718</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.hopper.2015.882">Hopper
RK, Feinstein
JA, Manning
MA, Benitz
W, Hudgins
L. Neonatal pulmonary arterial hypertension and Noonan <span class="term-highlight">syndrome</span>: two fatal cases with a specific RAF1 mutation.
Am J Med Genet A.
2015;167A:882-5.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25706034" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25706034</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.huang.2022.389">Huang
SJ, Amendola
LM, Sternen
DL. Variation among DNA banking consent forms: points for clinicians to bank on.
J Community Genet.
2022;13:389-97.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314484/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC9314484</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35834113" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 35834113</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.huckstadt.2021.1256">Huckstadt
V, Chinton
J, Gomez
A, Obregon
MG, Gravina
LP. Noonan <span class="term-highlight">syndrome</span> with loose anagen hair with variants in the PPP1CB gene: First familial case reported.
Am J Med Genet A.
2021;185:1256-60.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/33491856" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 33491856</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.jafarov.2005.190">Jafarov
T, Ferimazova
N, Reichenberger
E (2005) Noonan-like <span class="term-highlight">syndrome</span> mutations in PTPN11 in patients diagnosed with cherubism.
Clin Genet
68:190-1
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15996221" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15996221</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.jenkins.2020.e002690">Jenkins
J, Barnes
A, Birnbaum
B, Papagiannis
J, Thiffault
I, Saunders
CJ. LZTR1-related hypertrophic cardiomyopathy without typical Noonan <span class="term-highlight">syndrome</span> features.
Circ Genom Precis Med.
2020;13:e002690.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/32004086" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32004086</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.johnston.2018.1175">Johnston
JJ, van der Smagt
JJ, Rosenfeld
JA, Pagnamenta
AT, Alswaid
A, Baker
EH, Blair
E, Borck
G, Brinkmann
J, Craigen
W, Dung
VC, Emrick
L, Everman
DB, van Gassen
KL, Gulsuner
S, Harr
MH, Jain
M, Kuechler
A, Leppig
KA, McDonald-McGinn
DM, Can
NTB, Peleg
A, Roeder
ER, Rogers
RC, Sagi-Dain
L, Sapp
JC, Schäffer
AA, Schanze
D, Stewart
H, Taylor
JC, Verbeek
NE, Walkiewicz
MA, Zackai
EH, Zweier
C, Zenker
M, Lee
B, Biesecker
LG, et al.
Autosomal recessive Noonan <span class="term-highlight">syndrome</span> associated with biallelic LZTR1 variants.
Genet Med.
2018;20:1175-85
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105555/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6105555</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29469822" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29469822</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.jongmans.2004.56">Jongmans
M, Otten
B, Noordam
K, van der Burgt
I (2004) Genetics and variation in phenotype in Noonan <span class="term-highlight">syndrome</span>.
Horm Res
62
Suppl 3:56-9
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15539800" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15539800</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.jongmans.2010.635">Jongmans
MC, Hoogerbrugge
PM, Hilkens
L, Flucke
U, van der Burgt
I, Noordam
K, Ruiterkamp-Versteeg
M, Yntema
HG, Nillesen
WM, Ligtenberg
MJ, van Kessel
AG, Kuiper
RP, Hoogerbrugge
N (2010) Noonan <span class="term-highlight">syndrome</span>, the SOS1 gene and embryonal rhabdomyosarcoma.
Genes Chromosomes Cancer.
49:635-41.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/20461756" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20461756</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.jongmans.2011.870">Jongmans
MC, van der Burgt
I, Hoogerbrugge
PM, Noordam
K, Yntema
HG, Nillesen
WM, Kuiper
RP, Ligtenberg
MJ, van Kessel
AG, van Krieken
JH, Kiemeney
LA, Hoogerbrugge
N (2011) Cancer risk in patients with Noonan <span class="term-highlight">syndrome</span> carrying a PTPN11 mutation.
Eur J Hum Genet.
19:870-4.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172922/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3172922</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21407260" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21407260</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.j_nsson.2017.519">Jónsson
H, Sulem
P, Kehr
B, Kristmundsdottir
S, Zink
F, Hjartarson
E, Hardarson
MT, Hjorleifsson
KE, Eggertsson
HP, Gudjonsson
SA, Ward
LD, Arnadottir
GA, Helgason
EA, Helgason
H, Gylfason
A, Jonasdottir
A, Jonasdottir
A, Rafnar
T, Frigge
M, Stacey
SN, Th Magnusson
O, Thorsteinsdottir
U, Masson
G, Kong
A, Halldorsson
BV, Helgason
A, Gudbjartsson
DF, Stefansson
K. Parental influence on human germline de novo mutations in 1,548 trios from Iceland.
Nature.
2017;549:519-22.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/28959963" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28959963</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.jung.2003.330">Jung
A, Bechthold
S, Pfluger
T, Renner
C, Ehrt
O.
Orbital rhabdomyosarcoma in Noonan <span class="term-highlight">syndrome</span>.
J Pediatr Hematol Oncol.
2003;25:330-2.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/12679651" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12679651</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.keh.2013.749">Keh
YS, Abernethy
L, Pettorini
B. Association between Noonan <span class="term-highlight">syndrome</span> and Chiari I malformation: a case-based update.
Childs Nerv Syst.
2013;29:749-52.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/23239255" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23239255</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.khan.1995.743">Khan
S, McDowell
H, Upadhyaya
M, Fryer
A. Vaginal rhabdomyosarcoma in a patient with Noonan <span class="term-highlight">syndrome</span>.
J Med Genet.
1995;32:743-5.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1051679/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1051679</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8544198" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8544198</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.kratz.2015.1392">Kratz
CP, Franke
L, Peters
H, Kohlschmidt
N, Kazmierczak
B, Finckh
U, Bier
A, Eichhorn
B, Blank
C, Kraus
C, Kohlhase
J, Pauli
S, Wildhardt
G, Kutsche
K, Auber
B, Christmann
A, Bachmann
N, Mitter
D, Cremer
FW, Mayer
K, Daumer-Haas
C, Nevinny-Stickel-Hinzpeter
C, Oeffner
F, Schlüter
G, Gencik
M, Überlacker
B, Lissewski
C, Schanze
I, Greene
MH, Spix
C, Zenker
M. Cancer spectrum and frequency among children with Noonan, <span class="term-highlight">Costello</span>, and cardio-facio-cutaneous syndromes.
Br J Cancer.
2015;112:1392-7.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402457/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4402457</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25742478" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25742478</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.kratz.2009.1036">Kratz
CP, Zampino
G, Kriek
M, Kant
SG, Leoni
C, Pantaleoni
F, Oudesluys-Murphy
AM, Di Rocco
C, Kloska
SP, Tartaglia
M, Zenker
M. Craniosynostosis in patients with Noonan <span class="term-highlight">syndrome</span> caused by germline KRAS mutations.
Am J Med Genet A.
2009;149A:1036-40
 [<a href="https://pubmed.ncbi.nlm.nih.gov/19396835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19396835</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.lee.2014.1171">Lee
A, Sakhalkar
MV. Ocular manifestations of Noonan <span class="term-highlight">syndrome</span> in twin siblings: a case report of keratoconus with acute corneal hydrops.
Indian J Ophthalmol.
2014;62:1171-3.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313503/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4313503</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25579364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25579364</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.lee.2005a.35">Lee
DA, Portnoy
S, Hill
P, Gillberg
C, Patton
MA (2005a) Psychological profile of children with Noonan <span class="term-highlight">syndrome</span>.
Dev Med Child Neurol
47:35-8
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15686287" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15686287</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.lee.2015.17">Lee
PA, Ross
JL, Pedersen
BT, Kotnik
P, Germak
JA, Christesen
HT. Noonan <span class="term-highlight">syndrome</span> and Turner <span class="term-highlight">syndrome</span> patients respond similarly to 4 years' growth-hormone therapy: longitudinal analysis of growth-hormone-naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program.
Int J Pediatr Endocrinol.
2015;2015:17.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562101/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4562101</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26351466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26351466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.lee.2005b.7">Lee
WH, Raas-Rotschild
A, Miteva
MA, Bolasco
G, Rein
A, Gillis
D, Vidaud
D, Vidaud
M, Villoutreix
BO, Parfait
B. Noonan <span class="term-highlight">syndrome</span> type I with PTPN11 3 bp deletion: structure-function implications.
Proteins.
2005b;58:7-13
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15521065" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15521065</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.linglart.2020.73">Linglart
L, Gelb
BD. Congenital heart defects in Noonan <span class="term-highlight">syndrome</span>: diagnosis, management, and treatment.
Am J Med Genet C Semin Med Genet.
2020;184:73-80.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682536/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7682536</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32022400" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32022400</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.lissewski.2015.2685">Lissewski
C, Kant
SG, Stark
Z, Schanze
I, Zenker
M. Copy number variants including RAS pathway genes-how much RASopathy is in the phenotype?
Am J Med Genet A.
2015;167A:2685-90.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25974318" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25974318</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.lissewski.2021.51">Lissewski
C, Chune
V, Pantaleoni
F, De Luca
A, Capri
Y, Brinkmann
J, Lepri
F, Daniele
P, Leenders
E, Mazzanti
L, Scarano
E, Radio
FC, Kutsche
K, Kuechler
A, Gérard
M, Ranguin
K, Legendre
M, Vial
Y, van der Burgt
I, Rinne
T, Andreucci
E, Mastromoro
G, Digilio
MC, Cave
H, Tartaglia
M, Zenker
M. Variants of SOS2 are a rare cause of Noonan <span class="term-highlight">syndrome</span> with particular predisposition for lymphatic complications.
Eur J Hum Genet.
2021;29:51-60.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852574/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7852574</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32788663" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32788663</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.lodi.2020.582">Lodi
M, Boccuto
L, Carai
A, Cacchione
A, Miele
E, Colafati
GS, Diomedi Camassei
F, De Palma
L, De Benedictis
A, Ferretti
E, Catanzaro
G, Pò
A, De Luca
A, Rinelli
M, Lepri
FR, Agolini
E, Tartaglia
M, Locatelli
F, Mastronuzzi
A. Low-grade gliomas in patients with Noonan <span class="term-highlight">syndrome</span>: case-based review of the literature.
Diagnostics (Basel). 2020;10:582.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460327/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7460327</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32806529" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32806529</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.luo.2012.1918">Luo
C, Yang
YF, Yin
BL, Chen
JL, Huang
C, Zhang
WZ, Wang
J, Zhang
H, Yang
JF, Tan
ZP. Microduplication of 3p25.2 encompassing RAF1 associated with congenital heart disease suggestive of Noonan <span class="term-highlight">syndrome</span>.
Am J Med Genet A.
2012;158A:1918-23.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/22786616" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22786616</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.marks.2008.5524">Marks
JL, Gong
Y, Chitale
D, Golas
B, McLellan
MD, Kasai
Y, Ding
L, Mardis
ER, Wilson
RK, Solit
D, Levine
R, Michel
K, Thomas
RK, Rusch
VW, Ladanyi
M, Pao
W (2008) Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.
Cancer Res.
68:5524-8.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2586155/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2586155</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18632602" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18632602</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.martinelli.2010.250">Martinelli
S, De Luca
A, Stellacci
E, Rossi
C, Checquolo
S, Lepri
F, Caputo
V, Silvano
M, Buscherini
F, Consoli
F, Ferrara
G, Digilio
MC, Cavaliere
ML, van Hagen
JM, Zampino
G, van der Burgt
I, Ferrero
GB, Mazzanti
L, Screpanti
I, Yntema
HG, Nillesen
WM, Savarirayan
R, Zenker
M, Dallapiccola
B, Gelb
BD, Tartaglia
M. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan <span class="term-highlight">syndrome</span>-like phenotype.
Am J Hum Genet.
2010;87:250-7.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917705/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2917705</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20619386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20619386</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.martinelli.2015.787">Martinelli
S, Stellacci
E, Pannone
L, D'Agostino
D, Consoli
F, Lissewski
C, Silvano
M, Cencelli
G, Lepri
F, Maitz
S, Pauli
S, Rauch
A, Zampino
G, Selicorni
A, Melançon
S, Digilio
MC, Gelb
BD, De Luca
A, Dallapiccola
B, Zenker
M, Tartaglia
M. Molecular diversity and associated phenotypic spectrum of germline CBL mutations.
Hum Mutat.
2015;36:787-96.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25952305" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25952305</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.masonsuares.2017.509">Mason-Suares
H, Toledo
D, Gekas
J, Lafferty
KA, Meeks
N, Pacheco
MC, Sharpe
D, Mullen
TE, Lebo
MS. Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan <span class="term-highlight">syndrome</span>.
Eur J Hum Genet.
2017;25:509-11.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386422/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5386422</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28098151" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28098151</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.mcfarlane.2016.102">McFarlane
J, Knight
T, Sinha
A, Cole
T, Kiely
N, Freeman
R. Exostoses, enchondromatosis and metachondromatosis; diagnosis and management.
Acta Orthop Belg.
2016;82:102-5.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/26984661" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26984661</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.miri.2018.7698052">Miri
O, Bonnet
N, Lysy
P, Loucheur
N, Gayito
R, Docquier
PL. Multifocal pigmented villonodular synovitis in the Noonan <span class="term-highlight">syndrome</span>.
Case Rep Orthop.
2018;2018:7698052.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305014/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6305014</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30631623" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30631623</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.mitsuhara.2014.6">Mitsuhara
T, Yamaguchi
S, Takeda
M, Kurisu
K.
Gowers' intrasyringeal hemorrhage associated with Chiari type I malformation in Noonan <span class="term-highlight">syndrome</span>.
Surg Neurol Int.
2014;5:6.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927095/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3927095</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24575321" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24575321</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.moniez.2018.409">Moniez
S, Pienkowski
C, Lepage
B, Hamdi
S, Daudin
M, Oliver
I, Jouret
B, Cartault
A, Diene
G, Verloes
A, Cavé
H, Salles
JP, Tauber
M, Yart
A, Edouard
T. Noonan <span class="term-highlight">syndrome</span> males display Sertoli cell-specific primary testicular insufficiency.
Eur J Endocrinol.
2018;179:409-18.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/30325180" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30325180</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.moschovi.2007.341">Moschovi
M, Touliatou
V, Papadopoulou
A, Mayakou
MA, Nikolaidou-Karpathiou
P, Kitsiou-Tzeli
S. Rhabdomyosarcoma in a patient with Noonan <span class="term-highlight">syndrome</span> phenotype and review of the literature.
J Pediatr Hematol Oncol.
2007;29:341-4
 [<a href="https://pubmed.ncbi.nlm.nih.gov/17483716" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17483716</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.motta.2019.1007">Motta
M, Fidan
M, Bellacchio
E, Pantaleoni
F, Schneider-Heieck
K, Coppola
S, Borck
G, Salviati
L, Zenker
M, Cirstea
IC, Tartaglia
M. Dominant Noonan <span class="term-highlight">syndrome</span>-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling.
Hum Mol Genet.
2019;28:1007-22
 [<a href="https://pubmed.ncbi.nlm.nih.gov/30481304" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30481304</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.motta.2020.1772">Motta
M, Sagi-Dain
L, Krumbach
OHF, Hahn
A, Peleg
A, German
A, Lissewski
C, Coppola
S, Pantaleoni
F, Kocherscheid
L, Altmüller
F, Schanze
D, Logeswaran
T, Chahrokh-Zadeh
S, Munzig
A, Nakhaei-Rad
S, Cavé
H, Ahmadian
MR, Tartaglia
M, Zenker
M. Activating MRAS mutations cause Noonan <span class="term-highlight">syndrome</span> associated with hypertrophic cardiomyopathy.
Hum Mol Genet.
2020;29:1772-83.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/31108500" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31108500</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.myers.2014.2814">Myers
A, Bernstein
JA, Brennan
ML, Curry
C, Esplin
ED, Fisher
J, Homeyer
M, Manning
MA, Muller
EA, Niemi
AK, Seaver
LH, Hintz
SR, Hudgins
L. Perinatal features of the RASopathies: Noonan <span class="term-highlight">syndrome</span>, cardiofaciocutaneous <span class="term-highlight">syndrome</span> and <span class="term-highlight">Costello</span> <span class="term-highlight">syndrome</span>.
Am J Med Genet A.
2014;164A:2814-21
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25250515" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25250515</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.nava.2007.763">Nava
C, Hanna
N, Michot
C, Pereira
S, Pouvreau
N, Niihori
T, Aoki
Y, Matsubara
Y, Arveiler
B, Lacombe
D, Pasmant
E, Parfait
B, Baumann
C, Heron
D, Sigaudy
S, Toutain
A, Rio
M, Goldenberg
A, Leheup
B, Verloes
A, Cave
H (2007) CFC and Noonan syndromes due to mutations in RAS/MAPK signaling pathway: genotype/phenotype relationships and overlap with <span class="term-highlight">Costello</span> <span class="term-highlight">syndrome</span>.
J Med Genet
44:763-71.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652823/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2652823</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17704260" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17704260</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.neumann.2009.420">Neumann
TE, Allanson
J, Kavamura
I, Kerr
B, Neri
G, Noonan
J, Cordeddu
V, Gibson
K, Tzschach
A, Krüger
G, Hoeltzenbein
M, Goecke
TO, Kehl
HG, Albrecht
B, Luczak
K, Sasiadek
MM, Musante
L, Laurie
R, Peters
H, Tartaglia
M, Zenker
M, Kalscheuer
V (2009) Multiple giant cell lesions in patients with Noonan <span class="term-highlight">syndrome</span> and cardio-facio-cutaneous <span class="term-highlight">syndrome</span>.
Eur J Hum Genet.
17:420-5.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2986220/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2986220</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18854871" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18854871</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.niemeyer.2010.794">Niemeyer
CM, Kang
MW, Shin
DH, Furlan
I, Erlacher
M, Bunin
NJ, Bunda
S, Finklestein
JZ, Sakamoto
KM, Gorr
TA, Mehta
P, Schmid
I, Kropshofer
G, Corbacioglu
S, Lang
PJ, Klein
C, Schlegel
PG, Heinzmann
A, Schneider
M, Starý
J, van den Heuvel-Eibrink
MM, Hasle
H, Locatelli
F, Sakai
D, Archambeault
S, Chen
L, Russell
RC, Sybingco
SS, Ohh
M, Braun
BS, Flotho
C, Loh
ML. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.
Nat Genet.
2010;42:794-800.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297285/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4297285</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20694012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20694012</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.niemeyer.2014.1653">Niemeyer
CM. RAS diseases in children.
Haematologica.
2014;99:1653-62.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222471/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4222471</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25420281" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25420281</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.niihori.2005.192">Niihori
T, Aoki
Y, Ohashi
H, Kurosawa
K, Kondoh
T, Ishikiriyama
S, Kawame
H, Kamasaki
H, Yamanaka
T, Takada
F, Nishio
K, Sakurai
M, Tamai
H, Nagashima
T, Suzuki
Y, Kure
S, Fujii
K, Imaizumi
M, Matsubara
Y (2005) Functional analysis of PTPN11/SHP-2 mutants identified in Noonan <span class="term-highlight">syndrome</span> and childhood leukemia.
J Hum Genet
50:192-202
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15834506" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15834506</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.niihori.2019.1233">Niihori
T, Nagai
K, Fujita
A, Ohashi
H, Okamoto
N, Okada
S, Harada
A, Kihara
H, Arbogast
T, Funayama
R, Shirota
M, Nakayama
K, Abe
T, Inoue
SI, Tsai
IC, Matsumoto
N, Davis
EE, Katsanis
N, Aoki
Y. Germline-activating RRAS2 mutations cause Noonan <span class="term-highlight">syndrome</span>.
Am J Hum Genet.
2019;104:1233-40.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562005/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6562005</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31130285" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31130285</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.noonan.2001">Noonan JA (2001) Cardiac findings in cardio-facio-cutaneous <span class="term-highlight">syndrome</span>: similarities to Noonan and <span class="term-highlight">Costello</span> syndromes. Proc Greenwood Gen Ctr</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.noonan.a">Noonan JA. Noonan <span class="term-highlight">syndrome</span>. In: Goldstein S, Reynolds CR, eds. <em>Handbook of Neurodevelopmental and Genetic Disorders in Adults.</em> New York: Guilford Press; 2005a:308-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF86">Noonan <span class="term-highlight">Syndrome</span> Guideline Development Group. <em>Management of Noonan <span class="term-highlight">Syndrome</span> – A Clinical Guideline</em>. University of Manchester: DYSCERNE. Available <a href="https://rasopathiesnet.org/wp-content/uploads/2014/01/265_Noonan_Guidelines.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2010. Accessed 3-16-22.</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.noordam.2008.203">Noordam
C, Peer
PG, Francois
I, De Schepper
J, van den Burgt
I, Otten
BJ. Long-term GH treatment improves adult height in children with Noonan <span class="term-highlight">syndrome</span> with and without mutations in protein tyrosine phosphatase, non-receptor-type 11.
Eur J Endocrinol.
2008;159:203-8.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/18562489" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18562489</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.noordam.2007.24">Noordam
K (2007) Expanding the genetic spectrum of Noonan <span class="term-highlight">syndrome</span>.
Horm Res
68:24-7
 [<a href="https://pubmed.ncbi.nlm.nih.gov/18174700" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18174700</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.nystr_m.2008.500">Nyström
A-M, Ekvall
S, Berglund
E, Björkvist
M, Braathen
G, Duchen
K, Enell
H, Holmberg
E, Holmlund
U, Olsson-Engman
M, Annerén
G, Bondeson
M-L (2008) Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.
J Med Genet
45:500-6.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/18456719" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18456719</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.nystr_m.2009.524">Nyström
AM, Ekvall
S, Allanson
J, Edeby
C, Elinder
M, Holmström
G, Bondeson
ML, Annerén
G. (2009) Noonan <span class="term-highlight">syndrome</span> and neurofibromatosis type I in a family with a novel mutation in NF1.
Clin Genet.
76:524-34.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/19845691" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19845691</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.ogawa.2004.61">Ogawa
M, Moriya
N, Ikeda
H, Tanae
A, Tanaka
T, Ohyama
K, Mori
O, Yazawa
T, Fujita
K, Seino
Y, Kubo
T, Tanaka
H, Nishi
Y, Yoshimoto
M (2004) Clinical evaluation of recombinant human growth hormone in Noonan <span class="term-highlight">syndrome</span>.
Endocr J
51:61-8
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15004410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15004410</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.osio.2005.1232">Osio
D, Dahlgren
J, Wikland
KA, Westphal
O (2005) Improved final height with long-term growth hormone treatment in Noonan <span class="term-highlight">syndrome</span>.
Acta Paediatr
94:1232-7
 [<a href="https://pubmed.ncbi.nlm.nih.gov/16203673" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16203673</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.pandit.2007.1007">Pandit
B, Sarkozy
A, Pennacchio
LA, Carta
C, Oishi
K, Martinelli
S, Pogna
EA, Schackwitz
W, Ustaszewska
A, Landstrom
A, Bos
JM, Ommen
SR, Esposito
G, Lepri
F, Faul
C, Mundel
P, López Siguero
JP, Tenconi
R, Selicorni
A, Rossi
C, Mazzanti
L, Torrente
I, Marino
B, Digilio
MC, Zampino
G, Ackerman
MJ, Dallapiccola
B, Tartaglia
M, Gelb
BD (2007) Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
Nat Genet
39:1007-12
 [<a href="https://pubmed.ncbi.nlm.nih.gov/17603483" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17603483</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.pauta.2022.26">Pauta
M, Martinez-Portilla
R, Borrell
A. Diagnostic yield of exome sequencing in fetuses with an isolated increased nuchal translucency: systematic review and meta-analysis.
Ultrasound Obstet Gynecol.
2022;59:26-32.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/34309942" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 34309942</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.pierpont.2016.14">Pierpont
EI. Neuropsychological functioning in individuals with Noonan <span class="term-highlight">syndrome</span>: a systematic literature review with educational and treatment recommendations.
J Pediatr Neuropsychol.
2016;2:14-33. Available <a href="https://link.springer.com/article/10.1007/s40817-015-0005-5/fulltext.html" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. Accessed 3-16-22.</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.pierpont.2015.385">Pierpont
EI, Tworog-Dube
E, Roberts
AE. Attention skills and executive functioning in children with Noonan <span class="term-highlight">syndrome</span> and their unaffected siblings.
Dev Med Child Neurol.
2015;57:385-92.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979240/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC9979240</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25366258" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25366258</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.pires.2021.3099">Pires
LVL, Bordim
RA, Maciel
MBR, Tanaka
ACS, Yamamoto
GL, Honjo
RS, Kim
CA, Bertola
DR. Atypical, severe hypertrophic cardiomyopathy in a newborn presenting Noonan <span class="term-highlight">syndrome</span> harboring a recurrent heterozygous MRAS variant.
Am J Med Genet A.
2021;185:3099-103.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/34080768" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 34080768</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.prendiville.2014.629">Prendiville
TW, Gauvreau
K, Tworog-Dube
E, Patkin
L, Kucherlapati
RS, Roberts
AE, Lacro
RV. Cardiovascular disease in Noonan <span class="term-highlight">syndrome</span>.
Arch Dis Child.
2014;99:629-34.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/24534818" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24534818</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.quaio.2013.1079">Quaio
CR, de Almeida
TF, Brasil
AS, Pereira
AC, Jorge
AA, Malaquias
AC, Kim
CA, Bertola
DR. Tegumentary manifestations of Noonan and Noonan-related syndromes.
Clinics (Sao Paulo). 2013;68:1079-83.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3752636/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3752636</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24037001" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24037001</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.richards.2015.405">Richards
S, Aziz
N, Bale
S, Bick
D, Das
S, Gastier-Foster
J, Grody
WW, Hegde
M, Lyon
E, Spector
E, Voelkerding
K, Rehm
HL, et al.
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Genet Med.
2015;17:405-24.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544753/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4544753</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25741868" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25741868</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.roberts.2013.333">Roberts
AE, Allanson
JE, Tartaglia
M, Gelb
BD. Noonan <span class="term-highlight">syndrome</span>.
Lancet.
2013;381:333-42.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267483/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4267483</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23312968" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23312968</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.roberts.2007.70">Roberts
AE, Araki
T, Swanson
KD, Montgomery
KT, Schiripo
TA, Joshi
VA, Li
L, Yassin
Y, Tamburino
AM, Neel
BG, Kucherlapati
RS (2007) Germline gain-of-function mutations in SOS1 cause Noonan <span class="term-highlight">syndrome</span>.
Nat Genet
39:70-4
 [<a href="https://pubmed.ncbi.nlm.nih.gov/17143285" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17143285</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.rodr_guez.2020.732">Rodríguez
FA, Castellón
L, Moreno
R, Paez
E, Aracena Álvarez
MI. Noonan <span class="term-highlight">syndrome</span> with multiple Giant cell lesions, management and treatment with surgery and interferon alpha-2a therapy: case report.
Birth Defects Res.
2020;112:732-9.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/32065515" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32065515</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.rohrer.2020.380">Rohrer
TR, Abuzzahab
J, Backeljauw
P, Birkegård
AC, Blair
J, Dahlgren
J, Júlíusson
PB, Ostrow
V, Pietropoli
A, Polak
M, Romano
A, Ross
J, Sävendahl
L, Miller
BS. Long-Term Effectiveness and Safety of Childhood Growth Hormone Treatment in Noonan <span class="term-highlight">Syndrome</span>.
Horm Res Paediatr.
2020;93(6):380-395.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/33440388" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 33440388</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.romano.2010.746">Romano
AA, Allanson
JE, Dahlgren
J, Gelb
BD, Hall
B, Pierpont
ME, Roberts
AE, Robinson
W, Takemoto
CM, Noonan
JA. Noonan <span class="term-highlight">syndrome</span>: clinical features, diagnosis, and management guidelines.
Pediatrics.
2010;126:746-59.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/20876176" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20876176</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.romano.2009.2338">Romano
AA, Dana
K, Bakker
B, Davis
DA, Hunold
JJ, Jacobs
J, Lippe
B. Growth response, near-adult height, and patterns of growth and puberty in patients with Noonan <span class="term-highlight">syndrome</span> treated with growth hormone.
J Clin Endocrinol Metab.
2009;94:2338-44.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/19401366" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19401366</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.runtuwene.2011.393">Runtuwene
V, van Eekelen
M, Overvoorde
J, Rehmann
H, Yntema
HG, Nillesen
WM, et al.
Noonan <span class="term-highlight">syndrome</span> gain-of-function mutations in NRAS cause zebrafish gastrulation defects.
Dis Model Mech.
2011;4:393–9.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3097460/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3097460</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21263000" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21263000</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.sana.2014.2069">Sana
ME, Spitaleri
A, Spiliotopoulos
D, Pezzoli
L, Preda
L, Musco
G, Ferrazzi
P, Iascone
M. Identification of a novel de novo deletion in RAF1 associated with biventricular hypertrophy in Noonan <span class="term-highlight">syndrome</span>.
Am J Med Genet A.
2014;164A:2069-73.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/24782337" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24782337</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.sarkozy.2009.695">Sarkozy
A, Carta
C, Moretti
S, Zampino
G, Digilio
MC, Pantaleoni
F, Scioletti
AP, Esposito
G, Cordeddu
V, Lepri
F, Petrangeli
V, Dentici
ML, Mancini
GM, Selicorni
A, Rossi
C, Mazzanti
L, Marino
B, Ferrero
GB, Silengo
MC, Memo
L, Stanzial
F, Faravelli
F, Stuppia
L, Puxeddu
E, Gelb
BD, Dallapiccola
B, Tartaglia
M (2009) Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.
Hum Mutat.
30:695-702.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028130/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4028130</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19206169" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19206169</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.schubbert.2006.331">Schubbert
S, Zenker
M, Rowe
SL, Böll
S, Klein
C, Bollag
G, van der Burgt
I, Musante
L, Kalscheuer
V, Wehner
LE, Nguyen
H, West
B, Zhang
KY, Sistermans
E, Rauch
A, Niemeyer
CM, Shannon
K, Kratz
CP (2006) Germline KRAS mutations cause Noonan <span class="term-highlight">syndrome</span>.
Nat Genet
38:331-6
 [<a href="https://pubmed.ncbi.nlm.nih.gov/16474405" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16474405</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.seo.2018.176">Seo
GH, Yoo
HW. Growth hormone therapy in patients with Noonan <span class="term-highlight">syndrome</span>.
Ann Pediatr Endocrinol Metab.
2018;23:176-81.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312920/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6312920</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30599478" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30599478</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.sharland.1992.178">Sharland
M, Burch
M, McKenna
WM, Paton
MA. A clinical study of Noonan <span class="term-highlight">syndrome</span>.
Arch Dis Child.
1992;67:178-83.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1793396/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1793396</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1543375" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1543375</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.shchelochkov.2008.1042">Shchelochkov
OA, Patel
A, Weissenberger
GM, Chinault
AC, Wiszniewska
J, Fernandes
PH, Eng
C, Kukolich
MK, Sutton
VR (2008) Duplication of chromosome band 12q24.11q24.23 results in apparent Noonan <span class="term-highlight">syndrome</span>.
Am J Med Genet A
146A:1042-8
 [<a href="https://pubmed.ncbi.nlm.nih.gov/18348260" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18348260</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.shaw.2007.128">Shaw
AC, Kalidas
K, Crosby
AH, Jeffery
S, Patton
MA (2007) The natural history of Noonan <span class="term-highlight">syndrome</span>: a long-term follow-up study.
Arch Dis Child
92:128-32
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2083343/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2083343</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16990350" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16990350</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.smpokou.2012.3106">Smpokou
P, Tworog-Dube
E, Kucherlapati
RS, Roberts
AE. Medical complications, clinical findings, and educational outcomes in adults with Noonan <span class="term-highlight">syndrome</span>.
Am J Med Genet A.
2012;158A:3106-11.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/23165751" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23165751</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.stevenson.2006.246">Stevenson
DA, Viskochil
DH, Rope
AF, Carey
JC (2006) Clinical and molecular aspects of an informative family with neurofibromatosis type 1 and Noonan phenotype.
Clin Genet.
69:246-53.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243644/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3243644</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16542390" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16542390</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.stuurman.2019.654">Stuurman
KE, Joosten
M, van der Burgt
I, Elting
M, Yntema
HG, Meijers-Heijboer
H, Rinne
T. Prenatal ultrasound findings of rasopathies in a cohort of 424 fetuses: update on genetic testing in the NGS era.
J Med Genet.
2019;56:654-61.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/31040167" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31040167</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.suzuki.2019.1628">Suzuki
H, Takenouchi
T, Uehara
T, Takasago
S, Ihara
S, Yoshihashi
H, Kosaki
K.
Severe Noonan <span class="term-highlight">syndrome</span> phenotype associated with a germline Q71R MRAS variant: a recurrent substitution in RAS homologs in various cancers.
Am J Med Genet A.
2019;179:1628-30.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/31173466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31173466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.tartaglia.2002.1555">Tartaglia
M, Kalidas
K, Shaw
A, Song
X, Musat
DL, van der Burgt
I, Brunner
HG, Bertola
DR, Crosby
A, Ion
A, Kucherlapati
RS, Jeffery
S, Patton
MA, Gelb
BD (2002) PTPN11 mutations in Noonan <span class="term-highlight">syndrome</span>: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.
Am J Hum Genet
70:1555-63
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC379142/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC379142</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11992261" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11992261</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.tartaglia.2004.307">Tartaglia
M, Martinelli
S, Cazzaniga
G, Cordeddu
V, Iavarone
I, Spinelli
M, Palmi
C, Carta
C, Pession
A, Aricò
M, Masera
G, Basso
G, Sorcini
M, Gelb
BD, Biondi
A (2004) Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.
Blood
104:307-13
 [<a href="https://pubmed.ncbi.nlm.nih.gov/14982869" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14982869</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.tartaglia.2003.148">Tartaglia
M, Niemeyer
CM, Fragale
A, Song
X, Buechner
J, Jung
A, Hählen
K, Hasle
H, Licht
JD, Gelb
BD (2003) Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
Nat Genet
34:148-50
 [<a href="https://pubmed.ncbi.nlm.nih.gov/12717436" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12717436</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.tartaglia.2007.75">Tartaglia
M, Pennacchio
LA, Zhao
C, Yadav
KK, Fodale
V, Sarkozy
A, Pandit
B, Oishi
K, Martinelli
S, Schackwitz
W, Ustaszewska
A, Martin
J, Bristow
J, Carta
C, Lepri
F, Neri
C, Vasta
I, Gibson
K, Curry
CJ, Siguero
JP, Digilio
MC, Zampino
G, Dallapiccola
B, Bar-Sagi
D, Gelb
BD (2007) Gain-of-function SOS1 mutations cause a distinctive form of Noonan <span class="term-highlight">syndrome</span>.
Nat Genet
39:75-9
 [<a href="https://pubmed.ncbi.nlm.nih.gov/17143282" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17143282</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.tofil.2005.352">Tofil
NM, Winkler
MK, Watts
RG, Noonan
J (2005) The use of recombinant factor VIIa in a patient with Noonan <span class="term-highlight">syndrome</span> and life-threatening bleeding.
Pediatr Crit Care Med
6:352-4
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15857538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15857538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.van_der_burgt.2007.4">van der Burgt
I (2007) Noonan <span class="term-highlight">syndrome</span>.
Orphanet J Rare Dis
2:4.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781428/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1781428</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17222357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17222357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.van_der_burgt.1999.707">van der Burgt
I, Thoonen
G, Roosenboom
N, Assman-Hulsmans
C, Gabreels
F, Otten
B, Brunner
HG (1999) Patterns of cognitive functioning in school-aged children with Noonan <span class="term-highlight">syndrome</span> associated with variability in phenotypic expression.
J Pediatr
135:707-13
 [<a href="https://pubmed.ncbi.nlm.nih.gov/10586173" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10586173</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.van_nierop.2017.228">van Nierop
JWI, van Trier
DC, van der Burgt
I, Draaisma
JMT, Mylanus
EAM, Snik
AF, Admiraal
RJC, Kunst
HPM. Cochlear implantation and clinical features in patients with Noonan <span class="term-highlight">syndrome</span> and Noonan <span class="term-highlight">syndrome</span> with multiple lentigines caused by a mutation in PTPN11.
Int J Pediatr Otorhinolaryngol.
2017;97:228-34.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/28483241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28483241</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.van_trier.2018.1293">van Trier
DC, van der Burgt
I, Draaijer
RW, Cruysberg
JRM, Noordam
C, Draaisma
JM. Ocular findings in Noonan <span class="term-highlight">syndrome</span>: a retrospective cohort study of 105 patients.
Eur J Pediatr.
2018
Aug;177(8):1293-1298.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061046/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6061046</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29948256" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29948256</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.villani.2017.e83">Villani
A, Greer
MC, Kalish
JM, Nakagawara
A, Nathanson
KL, Pajtler
KW, Pfister
SM, Walsh
MF, Wasserman
JD, Zelley
K, Kratz
CP. Recommendations for cancer surveillance in individuals with RASopathies and other rare genetic conditions with increased cancer risk.
Clin Cancer Res.
2017;23:e83-e90.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/28620009" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28620009</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.vissers.2015.317">Vissers
LE, Bonetti
M, Paardekooper Overman
J, Nillesen
WM, Frints
SG, de Ligt
J, Zampino
G, Justino
A, Machado
JC, Schepens
M, Brunner
HG, Veltman
JA, Scheffer
H, Gros
P, Costa
JL, Tartaglia
M, van der Burgt
I, Yntema
HG, den Hertog
J. Heterozygous germline mutations in A2ML1 are associated with a disorder clinically related to Noonan <span class="term-highlight">syndrome</span>.
Eur J Hum Genet.
2015;23:317-24.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326711/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4326711</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24939586" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24939586</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.wilkinson.2012.442">Wilkinson
JD, Lowe
AM, Salbert
BA, Sleeper
LA, Colan
SD, Cox
GF, Towbin
JA, Connuck
DM, Messere
JE, Lipshultz
SE. Outcomes in children with Noonan <span class="term-highlight">syndrome</span> and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry.
Am Heart J
2012;164:442-8
 [<a href="https://pubmed.ncbi.nlm.nih.gov/22980313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22980313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.wolvius.2006.1289">Wolvius
EB, de Lange
J, Smeets
EE, van der Wal
KG, van den Akker
HP (2006) Noonan-like/multiple giant cell lesion <span class="term-highlight">syndrome</span>: report of a case and review of the literature.
J Oral Maxillofac Surg
64:1289-92
 [<a href="https://pubmed.ncbi.nlm.nih.gov/16860226" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16860226</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.yamamoto.2015.413">Yamamoto
GL, Aguena
M, Gos
M, Hung
C, Pilch
J, Fahiminiya
S, Abramowicz
A, Cristian
I, Buscarilli
M, Naslavsky
MS, Malaquias
AC, Zatz
M, Bodamer
O, Majewski
J, Jorge
AA, Pereira
AC, Kim
CA, Passos-Bueno
MR, Bertola
DR. Rare variants in SOS2 and LZTR1 are associated with Noonan <span class="term-highlight">syndrome</span>.
J Med Genet.
2015;52:413-21.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/25795793" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25795793</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.yaoita.2016.209">Yaoita
M, Niihori
T, Mizuno
S, Okamoto
N, Hayashi
S, Watanabe
A, Yokozawa
M, Suzumura
H, Nakahara
A, Nakano
Y, Hokosaki
T, Ohmori
A, Sawada
H, Migita
O, Mima
A, Lapunzina
P, Santos-Simarro
F, García-Miñaúr
S, Ogata
T, Kawame
H, Kurosawa
K, Ohashi
H, Inoue
S, Matsubara
Y, Kure
S, Aoki
Y.
Spectrum of mutations and genotype-phenotype analysis in Noonan <span class="term-highlight">syndrome</span> patients with RIT1 mutations.
Hum Genet.
2016;135:209-22.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/26714497" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26714497</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.yoon.2013.917">Yoon
SR, Choi
SK, Eboreime
J, Gelb
BD, Calabrese
P, Arnheim
N. Age-dependent germline mosaicism of the most common Noonan <span class="term-highlight">syndrome</span> mutation shows the signature of germline selection.
Am J Hum Genet.
2013;92:917-26.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682763/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3682763</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23726368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23726368</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.yoshida.2004.63">Yoshida
R, Miyata
M, Nagai
T, Yamazaki
T, Ogata
T (2004) A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan <span class="term-highlight">syndrome</span> including hydrops fetalis and juvenile myelomonocytic leukemia.
Am J Med Genet A.
128A:63-6.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/15211660" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15211660</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.zarate.2014.np13">Zarate
YA, Lichty
AW, Champion
KJ, Clarkson
LK, Holden
KR, Matheus
MG. Unique cerebrovascular anomalies in Noonan <span class="term-highlight">syndrome</span> with RAF1 mutation.
J Child Neurol.
2014;29:NP13-7.
 [<a href="https://pubmed.ncbi.nlm.nih.gov/23877478" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23877478</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.zavras.2015.71">Zavras
N, Meazza
C, Pilotta
A, Gertosio
C, Pagani
S, Tinelli
C, Bozzola
M. Five-year response to growth hormone in children with Noonan <span class="term-highlight">syndrome</span> and growth hormone deficiency.
Ital J Pediatr.
2015;41:71.
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595189/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4595189</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26444854" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26444854</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.zenker.2007.131">Zenker
M, Lehmann
K, Schulz
AL, Barth
H, Hansmann
D, Koenig
R, Korinthenberg
R, Kreiss-Nachtsheim
M, Meinecke
P, Morlot
S, Mundlos
S, Quante
AS, Raskin
S, Schnabel
D, Wehner
LE, Kratz
CP, Horn
D, Kutsche
K (2007) Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations.
J Med Genet
44:131-5
 [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2598066/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2598066</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17056636" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17056636</span></a>]</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
        <div class="post-content"><div><div class="half_rhythm"><a href="https://www.ncbi.nlm.nih.gov/books/about/copyright/">Copyright</a> © 1993-2024, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2024 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/GRcopyright_permiss/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/GRcopyright_permiss/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1124</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/20301303" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301303</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="https://www.ncbi.nlm.nih.gov/books/n/gene/" role="button" aria-expanded="false" aria-haspopup="true">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="https://www.ncbi.nlm.nih.gov/books/n/gene/tooth-agenesis-ov/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="https://www.ncbi.nlm.nih.gov/books/n/gene/leopard/" title="Next page in this title">Next &gt;</a></div></div></div></div>
        
    </div>
</div>
                        </div>
                        <div class="bottom">
                            <script type="text/javascript">
          var PBooksSearchTermData = {
            highlighter: "bold",
            dateTime: "07/08/2024 01:27:04",
            terms: [
        'costello', 'costello syndrome', 'syndrome'
            ]
          };
        </script>
                            <div id="NCBIFooter_dynamic">
    <!--<component id="Breadcrumbs" label="breadcrumbs"/>
    <component id="Breadcrumbs" label="helpdesk"/>-->
    
</div>

                            <script type="text/javascript" src="./Noonan-Syndrome-GeneReviews_files/InstrumentPageStarterJS.js.download"> </script>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div style="display: none;">External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div></div><div id="ZN_dikYWqsjiUWN0Q5"></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1124&amp;ncbi_domain=gene&amp;ncbi_report=printable&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1124/?report=printable&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- 11E0F089670CC1C3_7043SID /projects/books/PBooks@9.11 portal102 v4.1.r674589 Tue, Oct 31 2023 02:02:38 -->
<span id="portal-csrf-token" style="display:none" data-token="11E0F089670CC1C3_7043SID"></span>

<script type="text/javascript" src="./Noonan-Syndrome-GeneReviews_files/3426610.js.download" snapshot="books"></script>
<div tabindex="-1" role="dialog" class="ui-dialog ui-corner-all ui-widget ui-widget-content ui-front" aria-describedby="epubDialog" aria-labelledby="ui-id-1" style="display: none;"><div class="ui-dialog-titlebar ui-corner-all ui-widget-header ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making content easier to read in Bookshelf</span><button type="button" class="ui-button ui-corner-all ui-widget ui-button-icon-only ui-dialog-titlebar-close ui-state-default" title="Close"><span class="ui-button-icon ui-icon ui-icon-closethick"></span><span class="ui-button-icon-space"> </span>Close</button></div><div id="epubDialog" style="" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read books and documents     in Bookshelf.     Our first effort uses ebook readers, which have several "ease of reading"     features already built in.</p>  <p>The content is best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of some features of books or documents    in other eReaders.</p>  <button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button>  <button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download</button>        </div></div><script type="text/javascript" src="./Noonan-Syndrome-GeneReviews_files/saved_resource"></script></body></html>